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ABSTRACT 
Background and Aims: This study was designed to examine management practices of 
Canadian phy icians trained in the specialties of infectious disca es, gastroenterology and 
hepatology in order to increase understanding of how people living with the Hepatitis C 
Virus (H V) receive treatment aero s Canada. Approximately 170-175 million people 
worldwide are infected with HCV and the Cli!Tent prevalence of HCV in Canada is 
approximately 0.8%. It is known that treatment outcome and hence 
management trategies differ based on factor such as genotype and viral load, liver 
histology, body weight, co-infection with H!V and adherence. Canadian hepatologists 
have varied perspective toward treating HCV patients [ I]. The purpose of the study was 
to examine health care services provided to HCV patients by HCV health care providers 
(infectio us disease sp c ia lists, hepatologists, gastroenterologi t ) and to ee if there is 
variation in treating HCV in Canada. It is hypothesized that regional variation in 
treatment exists becau e of unequal acce s to care across Canada and that taffing 
capacity will be a major ban·ier to care. 
Methods: A nationwide anonymous postal survey was conducted to determine if 
treatment varies by geographical location. HCV health car provider were identified 
through the Canadian Medical Directory [2]. A cover letter outlining study objectives and 
a questionnaire were ent to all eligible HCV health care providers. The survey reque ted 
infonnation regarding health care provider demographics, referral pathway , treatment 
II 
eligibility, pattern of drug prescribing, bmTiers to providing high quality ervice, and the 
role of phy icians in providing treatment. 
Results: A structured questionnaire was sent to 562 physicians and 222 returned 
completed que tionnaire with an adjusted re ponse rate of 42%. Fotty-three percent of 
respondents provided a comprehensive service (included treatment and follow-up), 33% 
provided a diagnostic and investigative service (followed by referral to dedicated HCV 
service), and 24% had no role in the management and diagnosis of people with HCV. 
T he estimated number of patients managed by the total number of comprehensive service 
providers was over 27,000 with an increasing trend over the previous year . Regional 
variation was observed between comprehensive care providers across anada, including 
the size of practice community, number of patient , and type of service provided. The 
majority of comprehensive service providers indicated that they would not provide 
treatment to a current injection drug user; the provinces most likely to provide treatment 
were Alberta and Nova Scotia. Key barriers to quality of care identified by the majority 
of comprehensive service providers were funding for treatment and patient non-
attendance. 
Conclusions: Survey respondents revealed that there are regional vatiation acros 
Canada at many levels of the patient pathway, which could contribute to inequalities in 
health care services provided to patients with HCV. The results provide a baseline 
assessment of the overall HCV service acros Canada. Services involving a 
Ill 
multidisciplinary clinic setting need to be expanded and regional networks should be 
fonned in order to allow for a more comprehensive approach to the identification of HCV 
patients and health care delivery ofHCV antiviral therapy. 
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CHAPTER 1: INTRODUCTION 
1.1 Description of the Problem 
The treatment of patients with Hepatitis C in Canada is a population health issue 
and is therefore of utmost importance to all Canadians. Successful treatment of Hepatiti s 
C will greatly decrease the general population's risk of acquiring the infection. 
Futihermore, untreated patients can pose a threat to general public health. 
It is estimated that approximately 175 million people worldwide are infected with 
the Hepatitis C virus (HCV) [3]. In Canada, HCV is associated with excess mortality and 
infected individuals are more likely to have a reduced quality oflife (QoL) [ 4]. The 
estimated prevalence of HCV in Canada is 0.8% to 1%, which continues to be a dire 
economic and medical burden to Canadians [5]. In industrialised countries injection drug 
use is the leading risk factor for HCV infection [6]. Even though there is universal 
screening of the blood supply (eliminating this source of new cases of HCV infection), 
there are still over 4,500 new infections per year [5]. The risk of transmission is 
associated with sharing injection equipment such as needles and syringes as well as 
spoons, cottons and other injection paraphernalia [7]. ln Canada, we do not have a sense 
of how each province is providing HCV treatment to patients. In order to develop 
comprehensive strategies to address the HCV epidemic, it is vital to understand physician 
factors associated with HCV -related practice patterns. Thus, an inaugural nationwide 
survey was conducted to examine management practices of physicians trained in the 
specialties of infectious diseases, gastroenterology and hepatology. 
1.2 Purpose of the Study 
The present study has been undertaken to examine the pathways and services 
provided by HCV health care provider in the ten provinces of Canada 1 and the barrier 
that HCV health care providers might encounter while providing HCV treatment to 
patients. 
1.3 Research Question 
I propose to assess HCV health care providers ' (hepatologists, gastroenterologists 
and infectious disea e specialists) clinical practice pattems and how people living with 
HCV are managed in the health care system (i.e. refenal pattem , diagnosi and 
treatment). It is hypothesized that regional variation in treatment exists because of 
unequal access to care across Canada and that staffing capacity will be a major barrier to 
care. 
1.4 Rationale 
The aim of the above research is to examine the HCV management and treatment 
employed by physicians throughout Canada and dete1mine ifthere i geographical 
variation in treating HCY patients. Early treatment of HCV i e entia! to impede the 
progression of liver disease and the tudy will evaluate practices and understanding of 
physicians who treat HCV patients. Results derived from thi study will be able to 
identify regional variations in HCY practice, which has implications for improving HCV 
care. A national survey of cun·ent practices and service design need to be conducted in 
1 The Northwe t Territories, Yukon, and Nunavut were excluded from the study 
2 
order to establish baseline infonnation to plan future services for people living with 
HCV. 
In order to assess the geographical variation of HCV treatment in Canada, there is 
a need for a systematic approach to the identification, testing, refen·al , selection for 
treatment and follow-up of HCV positive patients. 
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CHAPTER2: BACKGROUND AND SIGNIFICANCE 
2.1 Hepatitis C Overview 
Hepatitis C Virus was identified in 1989 as ' non A, non 8 ' hcpatiti and is the 
most prevalent of the recognized hepatitis viruses in Canada and the United States [8]. 
There are a total of s ix viruses (A, B, C, D, E, and G) that account fo r the majority of 
viral hepatitis [9]. HCV belongs to the fl aviviridae family and is a single-stranded 
ribonucle ic acid (RNA) virus [10]. HCV has a narrow host range and onl y infects humans 
and chimpanzees. 
HCV vira l RNA and monostructural proteins have been fou nd in the liver of 
infected patients as well as in expetimentall y inoculated chimpazecs, confi rming that the 
liver is the site of HCV replication [ 12] . There is also strong evidence that HCV can 
replicate in peripheral mononuclear cell , both in vivo or in experi mentally infected B-
and T-ce1llines [ 12]. The HCV replicatio n cycle is based primaril y on analogies, due to 
the lack of a convenient animal model [12]. A hypothetical model of HCV replication can 
be summarized as fo llows (refer to Figure I): ( I) penetration of the host cell and 
liberation of the genomic RNA from the virus particle into the cytoplasm; (2) translation 
of the input RN A, processing of the polyprotein and fotm ation of a replicase com plex 
associated with intracellular membranes; (3) utilization of the input plus- trand for 
synthesis of a minus-strand RNA intem1ediate; ( 4) production of new pi us-strand RNA 
molecules which in turn can be used for synthesis of new minus strands, polyprotien 
expression or packaging into progeny virions; (5) release of virus from the infected cell. 
4 
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Figure 1: Hypothetical model of the HCV replication cycle 1121 
There is a high mutation rate in HCV that allows for a noticeable amount of 
genetic heterogeneity in the genome. Consequently there are 6 major HCV genotypes 
(with over 50 subtypes), with genotype I being the most widespread, fo llowed by 
gentoypes 2 and 3, found in approximately I 0%-20% of HCV patient in North America 
[ 11). A genotype is the genetic make up of a cell , individual , or organism. T he genotypes 
identified di ffer in viral pathogenicity, reponse to treatment, and overall prognosis [9). 
The qua ispecies nature of HCV has been proposed as a mechani m of viral 
persistence [ 13). V iral quasi species refers to closely related (but not identical) mutant and 
recombinant viral genomes subjected to continuous genetic variation, competition and 
selection [ 14). "Quasi" means resembling each other, and a quasi specie is created when 
RNA polymerase makes a mistake during HCY reproduction. These mi takes can create 
mutations, some of which are able to survive and therefore f01m HCV microvariant . The 
5 
production of variants is primarily due to the high error rate of the viral R A-dependent 
RNA polymerase (RdRp), which is expected to be in the range of I o-4 [ 12]. Errors are 
randomly introduced into the genome by the RdRp and because of the lack of 
proofreading function in these enzymes, errors remain uncoiTected [I 0]. The quasispccies 
ofHCV is suggested to be the mechanism by which HCV evades the control ofthe 
humoral and cellular immune response , allowing for a persi tent infection to prevail 
[ 13]. 
HCV is transmitted through contact with blood and blood products [ 15]. 
Presently, the primary cause of transmission is injection drug use, which accounts for 
roughly 60% of new and existing cases [ 16-18]. In addition, other modes of HCV 
transmission can occur through methods such as needle-stick injuries, blood transfusion, 
body piercing, tattooing, higher risk exual behaviour, and maternal-infant spread [ 19, 
20]. Moreover, HCV is often incorrectly perceived as dangerou and contagious to the 
community and i also falsely classified as a sexually transmitted disease2 [21 , 22]. 
The primary risk factors are well known, and they include blood transfusion 
before 1992, intravenous or intra-nasal drug use, and imprisonment (due to its reationship 
with drug use) [ 15, 23]. HCV is notably more infective than HIV following a needle-
stick injury (3% compared to 0.3%) [9]. In addition, it can take up to 6 months for 
seroconversion to occur in HCV; therefore, rigorous follow-up must be in place for 
patients at risk of contracting the virus. [9]. The disease can remain a ymptomatic tor 
many years. However, cirrhosis can develop unobtrus ively in 20%-30% of chronically 
2 It sho uld be no ted that 1-lCV is associated with higher-risk sexual behaviour (i .e. multiple partners, if 
partner is 1-llVcoinfected or exposure to blood during intercourse through trauma, mucosa l tears etc.). 
6 
.... 
... 
infected individuals over a period of20-30 y ars [8, 24]. HCY-rclated cirrhosis ha 
become the leading cause for liver transplantation in Notih Ameri ca [ I I]. At present, 
there are no effecti ve vaccines available fo r HCV [ 11 ]. 
7 
2.1.2 Background of Therapy for Hepatitis C 
The initial selection of interferon alfa (IFN-a) as a possible treatment for chronic 
HCV was empirical. The agent behind 'non-A, non-B' hepatitis had yet to be confinned, 
and specific drugs could not be designed because nothing was known about the viru ' 
virological characteristics [25]. The following sections chronicle HCV trea tment 
discoveries over the years, from monotherapy with IFN to specifi c HCV inhibitors. 
2.1.2.1 From Monotherapy to Combination 
The main objective for treatment i to annihilate the virus and prevent any 
complications from chronic HCV infection. The current treatment and standard of care 
for HCV is a combination ofpeginterferon and ribavirin [ 15]. In 1986, IFN-a 
demonstrated beneficial effects in patients with HCV before the virus was even identified 
[26]. IFNs are a class of cytokines produced by white blood cells that regulate the 
immune system and are involved in host defense [27]. Treatment with IFN-a 
subsequently led to a decline in HCV RNA, and successful responses were observed 
when HCV RNA was no longer detectable by currently available assays and chronic 
infection had been resolved [28]. IFN-a has antiviral activity but does not directly target 
the virus or any specific part of its replication cycle. IFN-a acts by inducing IF -
stimulated genes that are able to fonn a non-virus specific state within the cell [29, 30]. 
Nevertheless, monotherapy with IFN-a did not have a high sustained virological 
response (SVR) rate. An SVR occurs when a patient has a negative HCV viral load test 6 
months after the completion of HCV therapy. This response determines whether 
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treatment has been effective at clearing HCV. A 6-month course of therapy led to a 
sustained response of 6- 12%, and a 12-month course raised the rate to only 16-20% [31 ]. 
2.1.2.2 The Addition of Ribavirin 
Ribavirin was the first drug to be offered as an oral treatment for HCV [32]. 
Ribavirin wa created in 1970 as a guana ine analogue but was also observed to possess 
characterisiti c that act upon RNA and DNA vi ruses [33]. It should be mentioned that the 
exact mechani m that ribavirin uses to increase the response rate in combination with 
IFN-a remains unknown [25, 33, 34]. It is thought that ribavirin act on the production of 
v iral deoxyribonucleic acid (D A) and RNA, thus interfering with the replication and the 
survival ofthe virus [35] 
In the early 1990s, HCV monotherapy with ribavirin demonstrated improvements 
in serum aminotransferase levels in 50% of patients. However, viral load did not decrease 
and patients did not clear HCV, even after prolonged treatment [36, 37]. Alanine 
aminotransferase levels (AL T) decreased in all patients taking ribavirin. However, once 
treatment terminated they increased to pretreatment concentrations [32] . When the 
antiviral agent ribavirin was combined with IFN-a, treatment was improved and the 
sustained respon e rate doubled to 35-40% [25, 38]. Ribivirin wa then approved for 
therapy to treat chronic HCV patients but only in combination with IF -a. The treatment 
regimen consisted of IFN-a three times per week and a daily dose of ribavirin. In 1999, 
the European Association for the Study of the Liver Consensus onference approved 
ribavirin and IFN-a combination therapy as the standard treatment for HCV [39] 
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2.1.2.3 The Development of PEG-IFN-alpha 
Another major advancement was the creation of pegylated interferon (PEG-IFN). 
PEG-IF was developed by attaching poly( ethylene glycol) to recombinant IFN-a, 
which led to a molecule with a longer half-life and a better rate of virological response 
[40-42]. The fonnation of PEG-IF -a enabled treatment to be given once a week as 
opposed to three times, thus allowing for better adherence to treatment. There are two 
different fonns ofPEG-IFN available: PEG IFN-alpha-2a3 and PEG-1FN-alpha-2b4 . The 
size of the polyethylene glycol molecules bound to the IFN molecule is what 
distinguishes the two fonn from each other. Although the two forms have not been 
specifically evaluated to compare their effectiveness, they appear to obtain equi valent 
responses to therapy [ 4]. 
When PEG-IFN and ribavirin were given in combination the ustained response 
was increased to 54-56% [43, 44]. This can be seen as a major improvement. 
eve1iheless, these response rates have only been examined on selected populations and 
rarely do they include patients with co-morbidities and co-infections [ 45]. In 2002, the 
National lnsitutes of Health Consensus Developement Conference changed the standard 
of treatment for HCV to PEG-IFN-a combined w ith ribavirin. 
2.1.2.4 The Future of Therapy 
Through the unveiling of the 30 structure ofHCY, it is now possible to examine 
various functional viral elements (i .e. HC V prote ins and genome structures). This 
discovery has made it possible to target specific elements of HCY in order to screen and 
3PEG IFN-a lpha-2a is developed by Hoffmann-La Roche and is called Pegasys 
4 PEG-IFN-alpha-2b is developed by Schering-Piough and is called Pegetron. 
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develop specific small inhibitory molecules [ 46]. Thus, it is imaginable that specific 
inhibitors could be targeted for all steps of the HCV life cycle [25]. Cu1Tent targets 
consist of the HCV internal ribosome entry site (the RNA structure that initiates HCV 
polyprotein tran lation), HCV NSJ proteinase (the enzyme that en ures polyprotein 
processing downstream of the SJ- S4 junction), and HCV RNA-dependent R A 
polymerase (the enzyme that catalyzes HCV replication) [25]. 
There are many small molecule inhibitors cunently being evaluated which 
directly target HCV replication and have been shown to interfere with the ability of HCV 
to evade IFN. For instance, VX-950 specifically acts upon the S3-4A protease of HCV 
and has antiviral activity in vitro. In a tudy conducted by Reesink et al. [ 47] it was 
demonstrated that after 14 days of treatment with VX-950 all patients had at least a 2-
log10 decrease from baseline HCV RNA and two patients achieved undetectable levels. 
More notably, VX-950 was able to reduce viral load in a population of patients, 79% of 
which were previously non-responders to interferon based regimens [ 47]. 
The main cause of treatment failure when using specific inhibitors to target 
viruses, apa11 from non adherence to therapy, has been viral resistance [25]. 
Consequently, it is forseeable that viral resistance will occur if the small molecule 
inhibitors are used alone rather than in combination. There are a number of ways to evade 
viral resistance, such as reducing virus production by using highly potent antiviral 
molecules and using a combination of drugs with different viral targets [48]. 
II 
2.1.3 Hepatitis C Therapy Side Effects 
Patients undergoing HCV therapy need to be closely monitored because the s ide 
effects associated with PEG-IFN and ribavirin therapy can be severe and life-threatening 
[ 4]. The adverse effects can affect a patient' s ability to remain on treatment, lower their 
chances of attaining viral clearance and lessen their health-related quality of life [25]. 
Treatment is discontinued in 20-40% of patients due to severe dose-dependent side 
effects. In some cases doses are reduced, which effectively decreases the chance of 
achieving an SVR [49]. Monitoting side effects is paramount because it can help to avoid 
unnecessary treatment morbidity in patients who react poorly to therapy [50]. 
There are many medical contraindications for treatment with PEG-IFN and 
ribavirin (refer to Table I). Ribavirin is teratogenic5 in males and females and therefore 
contraception is advised during therapy and up to 6 months after therapy [51]. Other 
compl ications with combination treatment include hepatic decompensation in patients 
with citThosis and renal failure [52]. The two most common side-effects associated with 
ribavirin are hemolysis and anemia [52]. PEG-IFN side effects are linked to fatigue, 
muscle aches and psychological disorders such as depression, irritability, anxiety and 
sleep disturbance [52]. Moreover, interferon can also initiate pancytopenia, a reduction in 
red and white blood cells as well as platelets [ 44, 53]. Autoimmune thyroiditis has been 
observed to be the most common autoimmune reaction to therapy [53 , 54]. 
More serious side-effects include mood changes and depression [ 41 , 43, 44, 53]. 
If the symptoms are mild, they can be addressed by administering selective serotonin 
5 Able to disturb the development of an embryo or fetus 
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reuptake inhibitors [55]. Conversely, treatment must be discontinued if more severe 
depression or suicidal tendencies develop. Irregular ide-effects include hair thinning and 
loss, hearing impairment, insomnia, vi ual disorders, interstitial pneumonia, pancreatiti , 
and colitis [53 , 56]. 
Table l: Common side effects of hepatitis C treatment 
Pegylated-Interferon Ribavirin 
Flu-like symptoms Anemia 
-fever Hemolysis 
-chi ll s Birth defects 
-muscle and joint aches Cough 
-nausea and loss of appetite Shortness of breath 
Rash 
Reduction in red and white blood cells In omnia 
Hair loss 
Depression 
A study was recently conducted by Dan, Crone eta!. [57] that as essed anger as a 
neuropsychiatric side effect of fNF-a therapy. Results found that HCY patients 
demonstrated less control over their anger whi le taking IFN-a treatment, and angry 
reaction scores altered over the course of therapy [57]. The study observed a link between 
anger and depression, thus emphasizing the importance of monitoring patients receiving 
IF -a treatment [57] .The study also showed that there was an a sociation between anger 
resulting from the treatment and a negative effect on patients' health-related quality of 
life [57]. This study illustrated the need to assess proactive treatment of these 
neuropsychiatric side-effects in order to examine whether or not intervention will affect a 
patient's adherence to treatment and improve their well-being. 
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2.1.4 Responses and Strategies of Treatment 
A liver biop y is able to measure the extent of disease most effecti vely and is the 
o nly way to stage HCV accurately [58]. However, the practice of obtaining a li ver biopsy 
is cun·ently being debated [59]. General recommendations indicate that a biopsy should 
be performed regardless of AL T level bccau c A L T is not a good predictor of hepatic 
fibrosis when the re ults will influence whether or not treatment is recommended, 
however, it is not essential to initiate treatment [59]. Nevertheless, the li ver biopsy can 
be seen as a batTier to treatment for a number of patients [25]. Due to the fact that 75%-
90% of patients with genotype 2 or 3 will clear the virus with treatment [ 43 , 44], in 2002 
the National In titute of Health recommended that, in the absence of any 
contraindication , patients with genotype 2 or 3 do not have to undergo a liver biopsy and 
should begin treatment with PEG-IF and ribavirin [60]. Six rcspon es to therapy have 
been observed and defined: 
( I) Rapid virological re pon e (RVR) 
(2) Early virological response (EVR) 
(3) Partial virological re ponse (PVR) 
(4) Sustained virological rcspo n e (SVR) 
(5) Relapse 
(6) on-response 
An R VR represents a vital part of the treatment phase because it help d tetmin 
the duration of treatment and is the be t pred ictor of achieving an VR [ 4]. n RVR 
occurs when H V RNA is tested at week 4 and is undetectable. Therapy can then be 
shortened to 24 weeks for patients with genotype I and 12- 16 weeks for patients with 
genotype 2 and 3 [ 4]. An EVR occurs when there is non-detectable HCV R A at week 
12 of therapy [59]. PVR occurs when a 2 log drop in HCV R A i ob erved at week 
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12, however, HCV R A is still detectable [59]. An SVR refers to no detectable hepatitis 
C ribonucleic acid 6 months after completion of therapy and represents the goal of 
therapy [59]. One major factor that decreases a patient's chance of obtaining an SVR is 
advanced fibrosi or cirrhosis [61 , 62]. A relapse response occurs when viremia 
disappear and transaminases normalize but relapse withi n 6 months of the end of 
treatment [33]. A relapse response happens in I 0-25% of patient and the cause is not 
well understood but could be related to inadequate or absent do es of ribavirin [33]. It is 
possible to achieve an SVR in patient who have relapsed. However, thi u ually occur · 
using a longer course of treatment or higher do es [63]. on-respon e occurs in 
approximately one-third of patients with chronic HCV and the e patients never become 
HCV RNA negativc[33]. 
Treatment strategies differ ba cd on viral factors such a genotype, baseline viral 
loads, quasi pecisies diversity and acute versus chronic infection. Ho t factors include 
sex, race, age stage of fibrosis, body weight, body mass index, and co-morbid itie [33]. 
The cutTent treatment regime include a combination of PEG-IFN and ribavirin for 24 or 
48 weeks [31 ]. Viral genotype is the major predictor of SVR rates [50]. Genotype I has 
an SYR range from 42% to 46%, wherea SYR rates for gentoype 2 and 3 range from 
76-80% [33 , 43 , 44] . In addition, a low ba eline viral level has been ob erved to have 
improved rates of achieving an SVR [ 44]. Futi hermore, HCY re pon crate have been 
seen to differ in tetms of ethnic groups. For example African - Americans infected with 
HCY have a red uced chance of achieving SVR [64]. The basis for this ob ervation 
currently remain unknown. 
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2.1.5 Hepatitis C Diagnostic Tests 
Diagnostic tests are essential to determine the course of HCV treatment. The 
common approach is to first test for HCV antibodies (anti-HCV) and then to use HCV 
R A to confinn viremia [59]. A qualitative te tis used to detem1inc a po iti e or 
negative results; another quantitative tc t gives the viral load . It i very impo1tant to be 
consistent when u ing these assays because there is considerable inter-a say and intra-
assay variation with HCV R A testing [65]. The qualitative test can detect HCV RNA in 
the blood u ing techniques such a polymerase chain reaction (P R) or tran cription-
mediated amplification (TMA). The quantitative test uses target amplification (PCR, 
TMA) or s ignal amplification techniques to determine the amount of HCV RNA in the 
blood [59]. 
Quantitative HCV R Ate t have allowed physicians to evaluate the prognosis 
of HCV therapy and identify patients who are nonresponder early on, a well as patient 
who will conceivably achieve an SVR [59]. Moreover, HCV RNA tests can be used to 
identify acute infection because HCV RNA can be detected 1-2 weeks after exposure, 
while antibodie are usually detected 8 weeks after exposure [66, 67]. Furthermore, HCV 
R A testing can be implemented when a patient receives a negative anti -HCV test and 
they have already established condition a ociated with a diminished antibody 
production uch as HIV infection [68]. Thi situation occurs when a person fails to mount 
the appropriate host immune response due to immunodeficiency, which leads to a false 
negative anti-HCV. Con equently, the HCV R A test must be u ed to confirm infection. 
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Patient who test positive for HCV antibody are usually then offered additional 
tests to confirm the results. The presence of circulating virus is commonly confim1ed by 
vi ral load measurements and HCV polymerase chain reaction. A qualitative HCV RNA 
test at week 4 is used to detennine whether or not a RVR has been achieved. A week 12 
quantitative HCV RNA test is used to assess EVR, which is at least a 2-log drop in HCV 
RNA concentration from baseline. The Canadian guidelines state that this rule does not 
need to be applied rigorously because there is an inherent variabi li ty of0.5 logs in the 
HCV RNA assays. Therefore, the guidelines accept a 1.8 log decline in HCV RNA 
concentration from ba eline, which represent an EVR [50]. If a negative ensitive R A 
test is obtained in a person who tested positive for HCV antibodies, it is most likely that 
HCV infection has been resolved. This occurs when previous chronic HCV infection is 
either resolved spontaneously or is treatment-induced [59). 
T he week 12 test is perfonned on patients with genotype I, and failure to achieve 
an EVR initiates treatment withdrawal. It is now common practice to omit the week 12 
assessment of an EVR for genotypes 2 and 3 because almost all patients achieve one [50]. 
The Canadian guidelines also recommend a week 24 qualitative HCV RNA test for 
patients who achieved a PVR. If HCV RNA is detected at this time, treatment should be 
stopped at week 24 [50]. 
2.1.6 Dose and Duration ofTreatment 
As mentioned above, the cutTent treatment for HCV is a combination of PEG IFN 
alpha (2a or 2b) and ribavirin. There are s ix major genotypes [69] which can effectively 
predict the chance of responding to treatment and help detennine the duration of 
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treatment [43, 44]. For instance, 48 weeks oftherapy is given fo r genotypes 1,4,5 and 6. 
The treatment regimens are as follow :a weekly injection of 180 )..lg of PEG-IFN-alpha 
2a or 1.5 )..l.g/kg of PEG-IF -alpha 2b [ 4]. Ribavi rin is given in a do e of 800mg/day for 
patients with genotypes 2 and 3 and i do ed according to body weight for genotype I . 
The medication is taken orally in two divided doses. If an EVR has not been achieved 
after 24 weeks, treatment is stopped because the chance of ach ieving an SYR is minimal. 
Furthennore, genotypes 2 and 3 only require 24 weeks of therapy [4]. Recently it has 
been suggested that a shorter duration of treatment (12 weeks) might be pe1mitted for 
some patient infected with genotype 2 or 3 [70]. This alteration in treatment regimen has 
great implications for decreasing the prevalence of the disease because it could allow for 
more people to be wi lling to undergo HCV therapy. 
Adverse side-effects can lead to dose reduction. The most common reasons for 
dose reduction of ribavi1in and PEG-IF -a include neutropenia, thrombocytopenia and 
anemia [ 44, 53]. The main drawback of reducing the dosage of medication is that it could 
jeopordize the antiviral therapy outcome, thus having a negative effect on vira l 
eradication [34]. 
2.1.7 Acute and Chronic Hepatitis C 
Acute HCV is an interesting occurence in the progression of HCY. Most cases are 
asymptomatic and rarely diagnosed. This stage can go unnoti ced and is usually observed 
only under specifi c circumstances, such as when there is documented seroconversion and 
a known exposure [4]. lt is very difficult to conduct studie on patients with acute HCV-
infection becau e most of them do not develop symptom s, and therefore do not seek 
18 
medical attention and cannot be traced in medical records [59]. Futihem1ore, the HCV 
acutely infected patients that do have symptoms will most likely spontaneously clear the 
virus [66]. In general, high rates of spontaneous clearance have been observed following 
acute symptomatic infection [71 ]. Patients with acute HCV have a high rate of response 
to antiviral therapy and many become HCV R A negative regardle s of their viral load 
or genotype [72]. Thus, it can be suggested that non-response to therapy is acquired 
during chronic infection [33]. It is recommended that treatment for symptomatic acute 
HCV be delayed for the first 12 weeks, to allow for spontaneous clearance to occur and 
to avoid any unnecessary treatment [59]. However, treatment for asymptomatic acute 
HCV -infected patients should be started as soon as possible [59]. 
Testing for chronic HCV infection should be conducted on patients who have any 
risk factors for coming into contact with the virus. Risk factors include past or current 
injection drug use, blood transfusion before 1991 , and immigration fi:-om countries of 
high prevalence [73 , 74]. Patients with chronic HCV should be assessed on an individual 
basis to detennine whether or not therapy should be offered. Many factors need to be 
taken into consideration before treatment i initiated. These factors include risk of disea e 
progression to end stage, risk of adverse effects with therapy, and comorbid conditions. 
As well , other medical conditions need to be examined, such as hi tory of past or cutTent 
psychiatric disease, seizures, cardiac or renal disease, autoimmune disease, and alcohol or 
drug addiction [4]. Approximately 20% of chronically infected patients will develop 
cirrhosis over the next 20 years following acute infection, and roughly 3-5% of these 
patients will develop hepatocellular carcinoma (HCC) [34]. 
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2.1.8 Characteristics of Hepatitis C Patients 
The prognosis of chronic HCV is not well defined and varies on a case by case 
ba is. Nevertheless, a number of patients will eventually develop cirrhosis and HCC [65]. 
The lifetime risk of cirrhosis in HCV catTiers is e timated to be between 20-50%, with 
factors such as alcohol consumption identified as increasing the ri sk [34, 65]. 
As mentioned previously, the primary risk factor for HCV is injection drug use 
and studies have shown that exposure to HCV occurs in approximately 90% of injection 
drug users (IDUs) [75]. Despite thi high prevalence rate, very few ID Us with HCV have 
actually been treated with interferon-based antiviral therapy [76, 77] and prior to 2002 
current lDUs were not typically con idered for treatment [78]. This was due to the fact 
that in 1997 the National lnsitutes of Health (NIH) revealed in a consensu statement on 
the management ofHCV that IDUs should have a period of illicit drug use absti nence fo r 
6 months prior to HCV treatment6 [79). It should also be mentioned that the incidence of 
HCV infection is al o high in non-injection drug users compared to the general 
population, due to the sharing of non-injection equipment such as, pipes and straws [34]. 
The majority of HCV patients often have high rates of comorbidity which can 
include psychiatric illness, alcoholism and psychosocial instability [ 18, 34, 80]. Studies 
have demonstrated that many HCV patients have also concurrent diagnoses of mental 
health disorders such as depression, post-traumatic tress disorder, psychosi or anxiety 
[81 -83]. HCV patients are more likely to have these co-occuring illnesses when 
6 The NIH Consensus Statement: March 24-26, 1997 sta ted .. treatment of patie nts who are drinking 
s igni licant amounts of alcohol or who are actively using illicit drugs should be de layed until these habits 
are discontinued fo r at least 6 months."79. National Institutes ofHea/th Consensus Del'(!/opment 
Conference Statement: Management of hepatitis C: 1 997--March 24-26, 1997 
1997 [cited October 2nd 2007]; Available from: 
http ://consensus. nih.gov/ 1997 /1997HepatitisC I 05html.htm. 
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compared to the overall population. This can be seen as a major batTier to providing HCV 
treatment [80]. HCV patients should undergo psychiatric screening and counselling 
before commencing HCV therapy [80]. The Beck Depression Inventory is a creening 
tool used to monitor patients for depression and has been hown to perform the best in 
this type of analysis. 
In addition, many people living with HCV are coping with social is ues such a 
homelessness, lack of support and high mobility [ 4]. Subsequently, many of these 
"typical" patients were considered unsuitable for treatment because of concerns with 
adherence and stability and have been omitted from clinical trials . Thi omission is 
unjustifiable and studies have shown that only a mere I 0% of HCV lDUs who are 
eligible for treatment actually receive therapy [4, 76]. FUiihermore, succe ful treatment 
of HCV in IDUs may greatly decrease the general population ' risk of acquiring the 
infection [84] . In 20027 the NlH declared that eligibility for HCV treatment should be 
detern1ined on a case-by-case basi [60]. Consequently, there should be an individualised 
approach to delivering HCV therapy to patients. For instance, the decision to treat should 
be based on patient willingness to commence treatment, social conditions which can 
affect a patient' s stability and other medical comorbiditie that may hinder treatment 
[85]. 
7 The National Institutes of Health Consensus Statement: June l 0- 12, 2002 stated ' 'many patients with 
chronic hepatitis C have been ineligible for tria ls because of injection drug use, significant alcoho l use, age. 
and a number of comorbid medical and neuropsychiatric conditions. Efforts should be made to increase the 
availability of the best current treatments to these patients." Moreover, " it is recommended that treatment of 
active injection dmg use be considered on a case-by-case bas is, and that active injection drug use in and o f 
itself not be used to exclude such patients from antiviral therapy." 60. National i nstitutes of Health 
Consensus De1•elopment Conference Statement: Management of hepatitis : 2002--June I 0- I 2, 2002. 
Hepatology, 2002. 36(5 Suppl l ): p. S3-20. 
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Furthem1ore, it is uggested that adherence to antiviral therapy wil l be increased if 
patients are enrolled in interdisciplinary programs where there is collaboration between a 
hepatologist and an addictions counsellor in addition to stringent patient fo llow-up by a 
multidisciplinary team [86]. Regard less of whether or not a patient is an lOU or a non-
IDU a shared-care model offers a broader scope of care and is essential to improve the 
delivery of HCV treatment. The shared-care model involves a coordinated care team 
consisting of a hepatologist, family physcian, nurse speciali t, and psychiatrist [87, 88]. 
2.1.9 Hepatitis C in Injection Drug Users 
There is no guideline as to how to manage and treat HCY "real world"8 patient 
who is addicted to drugs and also coping with other complex medical conditions. These 
patients "may have poor adherence to health care regimens, high rates of comorbid 
p ychiatric illness, psychosocial instability, and poor health literacy" [89]. HCV-related 
service needs are not uniformly addressed because clinics and community health centres 
do not have a set national guideline for the treatment of HCV individuals who have 
multiple morbidities. This is a serious gap in care, which needs to be examined more 
thoroughly. 
Numerous stud ies have revealed that IDUs have had imliar compliance and 
treatment respon e rates compared to non-IDUs [84, 86, 87, 90-92]. For instance, Jeffrey, 
MacQuillan et al [87] revealed an SYR rate of 62% among 50 HCY patients undergoing 
opiate detoxification, whi ch is comparable to large contro lled clinical trails ofpegylated 
8 An I-ICY real world patient tends to have advanced liver disease, lengthy disease exposure, continuing 
drug use and is affected by psychosocial issues, such as housing, conditions, legal services, psychiatric 
disorders, and addictions. 
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PEG-lFN-a and ribavirin where the SVR rate was 54% and 63% [ 43, 44]. This study 
provided naltrexone implants for opiate dependency treatment. Naltrexonc is a long 
acting opiate antagonist that is non-addictive and produces no euphoria [93]. Despite the 
fact that methadone maintenance treatment is more commonly used than naltrexone it 
does not prevent people from using illicit drug even years after ta11ing the therapy [87]. 
These studies indicate that a rigid pretreatment abstinence duration should not be 
enforced. This will allow for willing and motivated HCV patients to receive therapy 
before achieving the designated 6 months sobriety, as long as they are supported by 
clinical and social support resources [92]. Moreover, it has al o been demonstrated that 
patients who do not completely abstain from alcohol can also be successfully treated [94]. 
In addition, methadone maintenance clinics offer an excellent resource to screen for 
HCV, thus identifying new patients for HCV therapy [80]. Consequently, the future of 
HCV treatment must recognize the "typical" patient and allow for treatment to be 
provided regardless of cu1Tent or fonner injection drug use. 
Directly observed therapy (DOT) is another approach that has been taken for the 
treatment ofHCV-infected lDUs. A study conducted by Grebely, Raffa et al. [85] 
revealed that 55% of pa11icipants achieved an SVR even though many patient continued 
to use illicit drugs during the course of their therapy. IF -a injections were directly 
observed and allowed for patients to receive continuity of care and access to education 
and support provided by the nurses administering the treatment [85]. The mode of 
delivering HCV treatment to IDUs must meet their complicated social needs and DOT 
program can provide a source of social support by providing a link to existing 
community-based organisations [95]. Consequently, pertinent issues such as housing and 
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food canal o be addressed, allowing for H V-infected IDUs to continue treatment. DOT 
can also act as a mode to enhance a trusting relationship between the patient and health-
care provider and facilitate patient engagement in harm reduction [95]. 
T he fear urrounding provision of treatment to IDUs such a compliance andre-
infection are not well substantiated [92]. Furthermore, there are no tudie that show 
abuse of drug reduces the effectiveness of interferon and ribavirin therapy [92]. De pite 
the fact that re-infection is a potential risk of ongoing injection drug u ers, studies have 
shown that it doc not occur as often as perceived [96, 97]. Adherence i vital in order for 
the course of therapy to be effective and is enhanced when the patient receives treatment 
from a multidisciplinary setting [4]. Even though effective HCV therapy i ava il able, less 
than one-third of patients in large HCV clinics have received treatment [98]. It is 
sugge ted that ub tance use behaviour hould be stabilised prior to treatment because 
HCV is generall y not an emergency to treat and the outcome of treatment will most likely 
be improved [92]. evertheless, thi all depends on the advancement of liver disease 
because 20% of active HCV cases will develop cirThosis after 20-30 year of infection 
[60]. 
It i important to acknowledge the fact that HCV is not the only medical condition 
fi·om which many patients suffer. Addiction i also a medical condition for which patients 
must receive treatment. Methadone and buprenorphine are very effective at reducing drug 
use and can help to stabilize patients. Nevertheless, it is important to recognize the 
neurochemical backbone9 of addiction and the fact that neurochemical changes are slow 
9 A neurochemical backboneof addiction re lects the long tenn abuse of psychoactive substances which can 
cause neurochemical changes. A neurochemical is an organic mo lecule that participates in neural activity. 
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to resolve and in some cases are irreversible [89]. However, this should not deter 
providing care to HCV infected IDUs a drug use alone is not a barrier to successful 
HCV treatment outcomes [89]. Thus, when providing treatment to HCV patients, a 
myriad of medical conditions must also be treated in order for HCV treatment to be 
effective. 
2.1.10 Obstacles to Providing HCV Treatment to People Using Injection Drugs 
fnjection drug users are underrepresented when compared to other patients 
receiving treatment for HCV infection [77, 99]. The reason for this imbalanced provision 
of care has to do with the fact that IDUs face multiple bmTiers to receiving treatment. 
These baniers manifest themselves on different levels: (I) the individual level ; (2) the 
provider level [77]; and (3) the environmental level [I 00, I 01]. 
2.1.10.1 The Individual Level 
A chaotic lifestyle can be an obstacle when attempting to provide HCV treatment 
to rDUs. For instance IDUs who were dependent on alcohol were much less likely to seek 
treatment for HCV infection [I 02]. Futihennore, adherence to treatment is another ban·icr 
that is often brought up when examining whether or not lDUs should be allowed 
treatment. HCV treatment regimens are arduous and require long-term dedication. 
Studies have hown that IDUs adhere poorly to treatment [103 , 104]; tudies also show 
that they adhere as well as other patients (non-lDUs) [105, 106]. Therefore, it is 
important to assess each lOU individually a they differ considerably from one to the 
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other. There are numerous other individual factors which affect the treatment of 10 s, 
such as depression, psychological stress, and lack of social support. 
A study conducted by Strathdee, Latka et al.[ 1 02] examined rca on why IOU 
were interested in seeking treatment. Patients who had a usual source of medical care 
were significantly more likely to be intere ted in treatment. Thi empha izes the 
importance of continuity of care among patients having to face important decisions with 
regards to HCV treatment. Moreover, more IDUs sought treatment when a doctor had 
told them that HCV could cause liver damage or liver cancer [102]. Therefore, it is 
impmiant to increase the use of health care in the IOU population in order to enhance the 
uptake of treatment. 
Low patient motivation can act as a deterent to seeking treatment. This may occur 
because patients are apprehensive about starting a toxic treatment that requir s injections, 
which may not ultimately result in a "cure". Moreover, IOUs may not be aware of the 
long-term etTect of HCV due to the fact that it can take many year to have symptom 
Thus, they are not concerned about eeking treatment [I 07]. An unstable lifestyle can 
impede treatment initiation and success. An addict can go through stages of their life 
when they are stable and drug free, to periods when they are heavy into alcohol and 
drugs. Furthem1ore, factors such as inconsi tent income, unstable housing frequent 
incarceration and lack of basic I ife essential such as meals, medications, and 
transportation all contribute to disorder and instability in one's life. Therefore, it can be 
difficult to commence and adhere to treatment when acute problems need to be addressed 
first. Active injection drug use has been a major barrier to providing HCV treatment and 
as a result numerous clinical trials have excluded individuals who are actively injecting 
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drugs. Nevertheless, studies have shown that treatment can be successfully provided to 
patients who are still injecting drugs [84]. Alcohol use is another ban·ier to care, as it is 
associated with the rapid progression of chronic hepatitis [99, I 07]. 
2.1.10.2 The Provider Level 
Re-infection is often a reason fo r withholding treatment from IDUs w ith HCV. 
However, it has been found that spontaneous clearance of HCV may actually award 
protection again t re-infection, thus providing a stronger impetus to treat IDUs [ I 08]. 
T iming of treatment is another factor to consider when examining IDUs with HCV. 
Therefore, treatment mu t be assessed on an individual basis. For instance, it might be 
more appropriate for some patients to address thei r drug use before providing HCV 
therapy. For other patients, it might be more pertinent to begin HCV treatment before the 
di sease progresses any further [77]. 
Pati ent discrimination in the healthcare setting is another ob tacle that can impede 
IDU HCV treatment. A study conducted in A ustra li a revealed that many physicians 
believe that IDUs sho uld not be provided HCV treatment due to concerns about adverse 
effects, adherence to treatment and re-infectio n with HCV [34]. Most physicians 
withhold treatment from HCV infected alcohol or inj ection drug u ers until a 6-month 
period of abstinence has been achieved [ I 09] . This is an impractical condition 
considering the fact that pati ents with substance use disorders are subject to relapse [34]. 
In addition, some physicians still believe that cutTent IDUs are unable to gain access to 
government funded treatment for HCV, which was the case in Au tra lia until May 200 I. 
Currently they are able to gain access to government funded treatment, but uptake has 
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remained low (34, II OJ. Moreover, a provider may not supply treatment if a patient is 
HIV/HCV co- infected as it could be burdensome and ineffective, thus compromising the 
HIV treatment [I 07]. 
2.1.10.3 The Environmental Level 
Environmental baiTiers exist even when individual and provider barriers are not 
apparent. The c can consist of lack of access to basic needs, such as housing, 
transportation, childcare, and a primary health care physician. Low rates of HCV 
treatment for 10 may al o be due to the lack of acce s to primary hcalthcare. ID s 
often use emergency rooms as their primary ource for healthcare, and therefore may 
have limited opportunities to enter into H V treatment [ l 07]. 
2.1.11 Psychiatric Conditions 
Therapy should not be withheld from patients who arc at ri k of becoming 
depre sed whi le taking the treatment. Moreover, it has been shown that comorbidity of 
HCV infection and psychiatric di order did not negatively influence the adherence to 
HCV therapy and treatment outcomes [I II]. Many studies have hown upport for the 
use of IF -ba ed therapy for HCV patients who al o have active psychiatric illne ses 
and/or subtance u e disorders [84, 96, 11 2- 114]. 
If patient are depressed before they commence therapy, they arc at a higher risk 
of experiencing worse symptoms [4]. verthelc s, if patients become depressed, 
treatment hould not be te1minated becau c antidepressants can treat the symptoms 
effectively, allowing for the fu ll course of therapy to be undertaken [4]. Recent studies 
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have shown promi ing results; pretreatment with antidepressants appears to be an 
effective method for minimising IFN-related depression [ 11 5, 11 6]. Moreover, if HCV 
patients with a hi tory of depression are engaged in the shared-care model, a planned 
approach to preexisitng or IF -induced p ychiatric di orders can be taken [ 7]. Thi can 
be in the fom1 of prophylatic antidepressant therapy, which can allow for more patients to 
complete HCV treatment and achieve an SV R [85, 87]. Convcrsly, there are serious 
situations in which therapy must be withdrawn, and these include suicidal thoughts and 
development of mania. 
It is very difficult to engage HCV -infected patients in treatment. Several studie 
have indicated that no- how rates for initial appointments are roughly 50%, and many of 
those patient who do attend their appointment are not considered ideal candidiates due to 
comorbid psychiatric or substance use diagnosis [98, 117]. Consequently, changes in the 
method for which treatment is provided need to be made in order to incrca e the number 
of patients with comorbidities receiving H V therapy. Hence, HCV treatment needs to be 
inclusive and al low for management of p ychiatric and substance usc di orders in HCV 
patients and not i olate the treatment regimen to exclusively antiviral therapy [34]. 
2.1.12 HIV/ HCV Coinfection 
Each patient coinfected with HIV/H V mu t be approached with an 
individualized therapy in mind, allowing for extensive monitoring of side effects and 
treatment efficacy [118, 119]. Roughly 20% of HTV-infected patients areal o coinfectcd 
with HCV [ 120]. The duration of H V treatment is different for patient co infected with 
HIV/HCV. For genotype 2 or 3, treatment hould be more than 6 months; for genotype I 
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or 4, treatment should last for more than 12 months [ 121, 122]. SVR rates for coinfected 
patients range from 43% to 62% in genotypes 2 and 3 and from 16% to 38% in genotype 
1 after 48 weeks of therapy [ 4]. 
Prior to treatment initiation, CD4+ cells counts must be examined. If the patient i 
already on highly active antiretroviral therapy (HAART) and factors uch as I-ICY 
genotype, severity of liver disease, viral load and degree of suppression of H IV 
replication are taken into consideration, the patient can initiate I-ICY treatment as long as 
their CD4+ cell counts are between 200 and 350 cells/J..tl [ 121, 122]. I-llY catTiers with 
cell count less than 200 cells/)ll tend to have a low response rate to anti- I-ICY therapy. 
Moreover, lFN ba ed therapies cause a decline in CD4+ cell count, which can put 
patients at risk for developing opportunistic infections [123]. Consequently, I-ICY 
treatment cannot begin until CD4+ cell count have increased [ 121 , 122). 
The timing of treatment depends on the stage of both disease . If a patient has not 
yet been treated for either virus, it is recommended that HIV treatment should be delayed 
and HCV should be treated first [ 124]. Treating HCV first, could potentially decrease 
li ver toxicity and improve the ultimate outcome of antiretroviral therapy [ 124]. However, 
HCV treatment mu t coincide with a CD4+ cell count that will allow for an effective 
response. Otherwi e, HlV should be treated first with HAART therapy, which will 
hopefully a llow for a better response to the I-ICY treatment once HIV has been tabilized 
[ 119) [124]. 
Drug-drug interaction should be taken into consideration when developing 
treatment for a person coinfected with HIV/HCV. Ribavirin may interact with other 
nucleoside reverse transcriptase inhibitor used in treatment of H IV such as didanosine 
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and cause mithochondrial toxicity. Cases of lactic acidosis and pancreatitis have been 
reported [ 122). Therefore, in order to avoid this adverse reaction didanosinc should not 
be used when treating patients with PEG-IF and ribavirin[ 122). In addition, tavudine 
and zidovudine hould also be avoided because they have shown to be as ociated with an 
increased risk of hyperlactaemia or anaemia [ 125). 
2.2 Hepatitis C: Current Situation in Canada 
Chronic hepatitis C will become a major economic and medical burden in Canada 
over the next I 0-20 years as people who are ymptomatic with the disea e advance to 
end- tage li ver di ease and develop hepatocellular carcinoma [65]. There arc no large 
scale studies that have revealed the prevalence of chronic HCY in Canada [4]. However, 
the number of per on infected with H V in Canada is estimated to be 240,000 or 0. % 
of the total population, 0.96% in male and 0.53% in females [5]. It i e timated that 
approximately 5,000 new infections arc expected to occur each year, although the 
incidence could be a high as 8,000 [126]. In January 1999 HCY was reported in all 
provinces and territories across the country [ 127]. Aboriginal populations in Canada have 
a I 5%-20% percent po itive rate for anti-HCY antibodies, compared to less than I% for 
the general population [ 126]. Injection drug u ers represent an at-ri k population with the 
highest rate of acquiring HCV infection [5). Approximately one third of people infected 
with HCV in Canada do not know they have HCV because they have not been tested 
[ 128). 
In anada, HCV was first reported in Briti h Columbia in 1992; gradually, other 
provinces started to report the disease [ 129). lt is estimated that 90,000 to 160,000 
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Canadians were infected with HCV through infected blood or blood products between 
1960 and 1992 [ 130]. Presently, the primary route of transmission in Canada is injection 
drug use [ 126, 131 ]. Approximately 60% of injection drug users (IDUs) carry HCV, with 
ome cities having prevalence rates ranging as high as 90% in IDU populations [ 126]. 
Approximately 2,700 HCV positive Canadian women give birth annually [ 126]. Vertical 
HCV transmission from mother to child can carry a risk of 5 to l 0% [ 126] . However, if 
the mother is co-infected with H IV this risk is increased by up to 60% [ 126]. 
The management of HCV treatment varies throughout Canada. This can be seen 
in the responses to a urvey conducted by Wang, Yi et al [l]. This study revealed that 
Canadian hepatologists have varied per pective towards treating HCV patients [I]. 
Moreover, there is a lack of liver specialists in Canada, creating considerable treatment 
challenge [ 132]. Treatment intensity varies significantly by province. For example, only 
14% of Ontario residents who acquired HCV through blood transfusion between 1986-
1990 were treated. In contrast, 32% of the Manitoba residents were treated [ 133]. In 
addition, people living with HCV endure many baiTiers to treatment. For example, some 
provinces such as British Columbia will deny treatment to patients unless their liver 
enzyme level test at more than 1.5 times normal. This is despite the fact that some 
biopsies show significant liver damage but nonnal liver enzyme level [ 126] . 
Consequently, this can lead HCV patients to try and increase their liver enzyme levels 
through dangerous means, such as drinking excessive quantities of alcohol [ 126]. 
Treatment ofHCV has shown to be extremely cost effective. Every I pent on 
HCV combination therapy results in medical cost savings of approimately $4 [ 126]. The 
Canadian lnstitues of Health Research indicates that HCV costs the Canadian health care 
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system 500 million annually [126]. Thi cot could be reduced ifmore HCV patients 
were treated w ith PEG-IFN and ribavirin combination therapy. It is known that early 
detection and treatment are associated with better treatment outcomes [ 126]. It is 
predicted that approximately 20% of infected Canadians will de elop erious 
complication fi·om HCV, such as cirrhosi , liver failure and hepatocellular carcinoma 
(HCC) [24]. A a result, treatment and medical care will become more complex and 
expensive. It i estimated that $ 1 million is spent on an HCV patient from time of 
diagnoses to death, including medical co ts and the economic loss for that individual 
[ 126). Anti-viral medications can co t 20 000 per course of treatment, whereas liver 
fai lure can cost 50,000 with a tran plant exceeding I 00,000 [ 126]. Therefore, the cost-
effeetivene of H V treatment far outweighs treatment of end tage liver disease, and 
more importantly reduce transmission of the viru to other people. 
2.3 Treatment - Health Implications and Quality of Life 
Advancements in treatment have led H V to be deemed a "curable" disease [ 126, 
134]. PEG lFN and ribavirin enhances VR; however, this therapy has drawbacks. 
evertheles , the advancements made by using the drugs in combination are two to 
threefold time higher than what wa previou ly achieved by using interferon 
monotherapy [ 43, 44]. 
There are many health implications with HCV. These can include hepatic 
cirrhosis, liver fai lure, and HCC. In many cases, the only remaining option for survival is 
a liver tran plant. Unfortunately, there is a limited number of livers available for 
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transplantation on an annual basis 10 (126]. In addition, many complications are associated 
with a liver transplant, including HCY infection of the transplanted liver. 
More importantly, the major impact of the disease is chronic ill health [ 135] . 
These symptoms can include lassitude, nausea, headaches and problem with memory 
and concentration, which all compromi e the quality of life (QoL) of a person living with 
HCV [ 135, 136]. These ailments can cover the entire HCV di ease spectrum from mild to 
more advanced liver disease [ 135]. These reductions in QoL have a deleterious effect on 
a person liv ing with HCV because it can affect their physical , social and occupational 
functioning [ 137]. Canadian HCV patients have significantly lower health-related QoL 
scores on a physical and mental level, when compared with age-matched Canadian norms 
[ 13 7]. 
The side effects ofHCV medications can indeed worsen the QoL of a person 
li ving with HCY. There is an association between therapy with alpha interferon and 
multiple psychiatric side effects, which include sadness, depression, anxiety and 
initability [ 138]. These side effects are a major reason for early discontinuation of 
therapy, as 20-30% of patients develop o me degree of depression during therapy [ 43 , 
44]. The coping abilities of the individual li ving with HCV will detem1ine whether or not 
they are able to continue with treatment [ 139]. HCV patients tend to prefer the side 
effects of therapy sooner rather than later, especially if they wi ll retum to nonnal health 
after the treatment [ 139]. 
10 There are approximately 400 livers available for transplantation each year 126.Rmiona/e and 
recommendations(or a Canadian hepatitis C strategy. 2004 [cited; Available from: 
http://www.canhepc.net/pdf!canhepc_strategy_ marl 2.pd f. 
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Despite the notable benefit of treatment, there is an immense lack of financial 
support for medication. Almost 90% of people infected with HCV do not have access to 
effective treatment [ 126]. The drugs cost over $20,000 for a 48-week course of treatment, 
and in most cases the drugs are simply unaffordable for patients without private 
insurance. However, obtaining treatment is only part of the challenge towards re tored 
health. The side- effects from the medication, as mentioned above, can lead patients to 
tem1inate treatment and in extreme cases commit suicide [ 126]. ompletion of treatment 
is an arduous task and certain measures, such as adequate nutrition, housing and support 
need to be in place in order for it to be successful. 
There is limited infonnation on physicians' perceptions ofQoL for people living 
with HCY. In a study conducted by Patil , Cotler et al. [140] a utility ana lysis was used to 
assess physicians' perceptions of HCY-related health states and how their perspective on 
HCV affect the advice they give patients about the disease. The respondents in the study 
felt that HCV causes a dramatic reduction in health status and even without symptom or 
cirrhosis they thought that HCV carried a 12% decrement from lifespan without HCV 
[ 140]. Moreover, time spent on therapy was judged to be associated with a 53% reduction 
from good health [ 140]. 
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2.4 Determinants of Health 
The detetminants of health must be addressed when detem1ining what leads to 
risk behaviours, sub-optimal health status, and lack of access to HCV treatment. The 
Public Health Agency of Canada lists key factors, such as income and social status, 
gender, education and literacy, and employment as part of the complex interactions that 
affect one's health status (141]. Very few IDUs enter HCV treatment programs [ 126]. 
This may be due to the fact that other needs, such as hunger and homelessness, must be 
met before treatment is sought. Therefore, in order to address the issue of treatment it is 
pertinent to examine the impact of the detetminants of health and the complex 
interactions that are involved when evaluating HCV treatment accessibility. 
2.5 Discrimination and Stigmatization of People Living with HCV 
HCV is a chronic, transmissible, slowly progessive disease that is frequently 
associated with injection drug use (142]. It is due to this association that HCV infection 
can lead to stigmatizing experiences (20]. The stigima ofHCV can be related to concerns 
aboutjob loss, insurance, motigages, friendships, and prejudices and discrimination 
directed at the children of people living with HCV [ 126]. 
Furihennore, it is impotiant to note that discrimination is most common in the 
health-care setting [ 126, 143] . It is known that some General Practitioners (GPs 11 ) 
restrict access to health care for patients that inject drugs [ 144]. This can lead to reduced 
contact between lDUs and health-care services. As a result, beneficial services such as 
health promotion, HIV and HCV testing, hepatitis B vaccination (HBV) and entry into 
11 General Practitioners are also known as Primary Care Physicians and Family Practitioners 
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drug treatment cannot be provided [20, 143]. It is therefore crucial fo r health care 
workers who manage HCV patients to be aware of the impact that their atti tude has on 
the treatment outcome of their patients. Consequently, the QoL of people li ving with 
chronic HCV can be affected by perceived social stigmitization [ 142]. 
Stigmitization can occur in many constructs . It was fo und that people living with 
HCV reported stigmitization in the fonn of internalized shame, financial insecurity and 
social rej ection [1 42]. This can lead to isolati on, anxiety, and trouble coping with the 
disease [20]. In addition, HCV patients face negative stereotyping, especially since the 
disease tends to be a sociated with crim inal behaviour [20]. A sense of helplessness and 
loss of control leads people li ving with HCV to envision a bleak future. Moreover, 
private relationships with family can deteriorate, leading to a los of social support. This 
can have a negative affect on QoL and the ability to cope with the disease. 
Fut1hennore, stigmitization has also led to a lack of public awareness with regards 
to disease prevention and control. People living with HCV come from di verse 
backgrounds, and ethni city, race, education, occupati on, age, gender and social status do 
not act a barri ers to transmission [145]. Nevertheless, there is a general lack of support 
fo r programs to aid people with mental illness, substance users, pri o n populations and 
other marginalized populations [126]. As a result, treatment accessibility has been 
marred by the stereotyping and prejudices as ociated with HCV, consequently adversely 
affect ing efforts to treat people living with HCV. 
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2.6 Literature Review - Hepatitis C Management Surveys 
The high prevalence ofHCV has led many countries, such as France, Australia, 
Turkey, Italy, the United Kingdom, and the United States to assess the screening and 
management of HCV by community-based practitioners [23, 146-150] and primary care 
(internal medicine and family practice) physicians [ 151]. Primary care providers have 
been designated the ' gatekeepers ' for HCV care and w ill increasingly be the first to 
encounter patients with HCV infection [ 146, 151]. However, a number of studies 
demonstrate that primary care providers only care for a few HCV patients and refer the 
majority to sub-specialists [ 149, 150, 152]. 
A number of studies surveyed GPs and their knowledge and education needs 
sun·ounding HCV treatment, as well as their diagnosis and management of HCV 
infection [23, 144, 146, 147, 149, 150]. GPs have a vital role in the health system as they 
must be able to effectively identify patients at ri k for HCV [ 148, 152]. This is an 
important task for GPs because the early stages are often asymptomatic. In addition, they 
should be able to perform the proper diagnostic tests and make the appropriate referrals 
[ 148, 152]. 
Results from previous studies showed that there is a need for targeted education 
for physicians concerning HCV, and that HCV management trategie need to be tailored 
to the identified needs of the general practitioner [23, 14 7- 149]. For instance, physicians 
surveyed by Peksen, Canbaz et al. [ 146] erroneously identified sexual and vertical 
transmission as being major risk factors for HCV, and respondents demonstrated poor 
knowledge of treatment options for chronic HCV. It is quite common for a person 
infected with HCV to not be aware of their infection, and as a re ult GPs need to be 
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cognizant of the impact of HCV in order to reduce the burden of the disease on the health 
care system in tenns of morbidity costs [ 148]. In summary, the studies revealed that GPs 
have demonstrated a poor knowledge base and practice pattem when dealing with the 
treatment of HCV patients [23, 144, 146, 149, 151, 152]. For example Coppola, 
Karakousis et al. [ 151] observed that primary care residents tested for HCV in 
inappropriate situations and were unclear about cutTent HCY treatment regimens. Thi 
lack of adequate knowledge has evidently led to lower rates oftherapy [153] . 
In a tudy conducted by Shebab, Sonnad & Lok [ 149], it was shown that the 
maj01ity of GPs correctly identified the major risk factors of HCV; however, an 
unsettling number of GPs (25%) still considered blood transfusion in 1994 a significant 
risk factor for HCV infection. In addition, 19% of GPs that responded to the survey 
considered casual household contact to be a significant risk factor for HCY infection 
[149]. Other disconcetiing findings revealed that only 59% of the respondents rep01ted 
that they a k patients for HCV risk factors, and only 70% of the GPs would conduct tests 
on patients with risk factors for HCY, which could lead to under- diagnosis [ 149]. In 
relation to treatment ofHCV, only 52% of the respondents recommended combination 
therapy with interferon and ribavirin, despite the fact that large trials have revealed the 
effectiveness of interferon and ribavirin therapy, in contrast to interferon mono therapy 
[54]. 
The first national study ofGPs in Australia about HCV was conducted by Gupta, 
Shah et al. [ 154]. Re ults revealed that GPs identified the need for hospital and specialist 
suppoti. Moreover, the importance ofho pital-based multidisciplinary clinics was 
declared to be useful in the management of HCY care by 55% of re pondents since the 
39 
majority of HCV patients were refeiTed to specialists. The study also identified specific 
educational and resource needs to incorporate into HCV educational programs for GPs, 
such as therapeutics, interpretation of tests and pre- and post-test counselling. Another 
crucial finding revealed that only one third of respondents stated that they would discuss 
psychosocial aspects as part of initial management of patients with HCV. Consequently, 
the need to address social and mental health issues will also have to be added to 
educational strategies for GPs treating HCV. The data from the study has allowed for 
more effective models of HCV care to be explored and addres ed. 
Another Australian study that surveyed GPs who serve large non-Engli sh 
speaking migrant populations attempted to assess knowledge of risk factors , 
complications, currently recommended antiviral therapy, referral practice to speciali sts 
and difficultie encountered by practitioners and patients in accessing information about 
HCV [ 155]. This study was conducted because Australia receive many migrants from 
countries with a high prevalence ofHCV infection. The findings revealed a number of 
important issues pertaining to GPs' current management of chronic HCV infection and 
their knowledge base of HCV risk factors. The majority felt that they were well infonned, 
however, almost half of the respondents agreed that lifetime immunity occutTed or that 
they were uncettain about immunity. There were discrepancies about providing HBV and 
Hepatitis A V irus (HA V) vaccinations; for instance, 33% reported that they would only 
immunize against HBV and I 0% stated that no immunization was required [ 155). 
Fmthennore, the GPs surveyed incorrectly listed sexual transmission and vettical 
transmission of HCV as being imp01tant risk factors when the estimated transmission risk 
is 5% [ 156]. A ll respondents indicated that LDU was a risk factor, but only 34% stated 
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that HCV could be spread through the use of shared injecting paraphernalia. In tenns of 
providing referral to specialists, most GPs referred patients when ALT levels were 
elevated or when abnorn1alliver function tests were observed. It wa noted that 30% of 
respondents did not refer patients if they were not willing to undergo HCV antiviral 
therapy. This demonstrates that ome GPs view specialist liver clinics a solely treatment 
providers. In contrast, these clinics also offer coun elling and education; therefore, GPs 
should seek advice from specialists at any stage of the diagnosis. The majority of 
respondents ( 47%) stated that interferon and ribavirin therapy wa the best treatment 
available. Conversely, 25% listed interferon monotherapy or lamivudinc (commonly used 
in the treatment of HBV), which shows that physicians need regular updates on current 
treatments [ 155]. The study concluded that physicians require continuing access to the 
most up-to-date and accurate infom1ation on HCV treatment advance and care. It was 
suggested that different fonns of communication, such as succinct bulletins, lectures and 
Internet websites be adapted in order to focus on the management of HCV in high-ri k 
ethnic groups [ 155]. 
A study of HCV in Canada was presented at the Navigating L{/e with Hepatitis C 
Conference, held in Halifax, Nova Scotia between March 7-9 2006 [ 157]. The study 
evaluated physicians and HCV perceptions. A national survey of789 family physicians 
was conducted, and stratified random sampling was used with the College of Family 
Physicians database. The aim of the survey was to describe the current knowledge and 
attitudes regarding HCV care and affected patients. It was detennined that less than 50% 
of family doctors offer basic or advanced HCV care, despite the fact that famil y 
physicians believed that HCY screening is something that all family doctors can do. In 
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addition, it wa noted that ID Us do not present a problem for them. However, the 
physicians were les confident in their ability to treat and follow-up dependent patients, 
and they expect poor results. Moreover, they view provision of HCV care as pm1 of 
famil y practi ce but beli eve resources such as tests and investigations necessary to 
evaluate and treat patients are not easily accessed. The study had a response rate of 33%. 
Another Canadian study surveyed practicing hepatologists about their attitudes 
and practices regarding interferon and ribavirin combination therapy for HCV patients in 
Canada [1]. An anonymous fax/postal survey was sent out. The questions examined the 
likelihood of treating a patient with certai n clinical characteristics and opin ions regarding 
how the physician's treatment decision is influenced by other factors. It was concluded 
that there is substantial variation in opinion among Canadian hepatologists toward HCV 
patients. In a general survey, however, re pondents appear to fo llow published guideline 
in their practice. The response rate was 86.4 %. 
A recent study conducted by Litw in, Kunins et al. [ 158] evaluated HCY-related 
management practices carri ed out by substance abuse physicians. A urvey instrument 
adapted from a study by Shehab, Sonnad et al. [1 52] was used to assess physician, 
practice, and pati ent characteristi cs and HCV -related practice patterns with an overall 
response rate of 52%. Three major fi ndings were revealed from the study. The first found 
that substance abuse treatment physicians promote impot1ant areas of HCY-related care, 
such as screening lDUs for HCV, recommending HA V and HBV vaccinations to non-
immune HCV -infected patients and refetTal of HCV patients fo r treatment. Despite thi s 
fi nding, only half of the surveyed physicians referred thei r HCV -infected patients for 
treatment. Moreover, only 45% of physicians recommended HAY vaccinations and 35% 
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recommended HBV. The second finding stated that substance abuse treatment physicians 
who a lso provide primary medical care are more likely to screen for HCV antibod ies, 
recommend HA V and HBV vaccinations and refer to HCV specialists than physician 
who do not provide primary care. Lastly, only 9% of surveyed substance abuse treatment 
physician stated that they directly treat HCV-infected patients; however, a third said that 
they were willing to provide HCV antiviral treatment if they were provided with the 
necessary re ources and education [ 158]. Another crucial finding from the study reported 
that 39% of physicians do not screen most IDUs for HCV antibodies. Consequently, 
these poor screening practices will cause infected IDUs to remain unaware of their HCV 
status. The overall findings from the study provided suppoti for integrating substance 
abuse treatment and primary medical care to maximize care for chronic HCV [ 158]. 
A few studies have specifica lly surveyed gastroenterologi ts, hepatologi ts and 
infectious disease specialists [ 159, 160]. In a study conducted by Everhart, Stolar eta!. 
the target population for the survey was practitioners most familiar with the management 
ofHCV infection [160]. The reason for surveying specialists as opposed to general 
practitioners was because the specialists can be considered leaders who have the mo t 
influence to guide the management of patients with HCV. Furthetmore, a tudy 
conducted in the UK by Parkes, J ., P. Roderick, eta!.[ 159] aimed to determine workload, 
configuration and care processes of CutTent UK services available to manage patients 
with chronic HCV infection. Four specialties were targeted -Gastroenterology, Genito-
Urinary Medicine, Hepatology and Infectious Diseases. A postal questionnaire was sent 
out, and it revealed that there is inequity and variation in the management of people with 
chronic HCV in the UK. The key banicrs to care were staffing and funding of treatment. 
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The response rate for this study was 7 1 %. The methods used in the UK study were 
adapted as a model fo r the current study on HCV management in Canada. 
2.6.1 Coordinated Pathways of Care for Hepatitis C 
Communicati on amongst the various disciplines integrated into pathways of HCV 
care is vi ta l so that patients complete the full course of anti viral therapy. T he 
multidisciplinary coordinated pathway of care includes many players in the health fi eld, 
such as specialty nurses, addictions counsello rs, psychiatrists, and primary care providers. 
The primary care providers, as mentioned above, are key to recommending HCV therapy 
and therefore need to receive continuing education about the history and treatment of 
HCV to provide optimal advice to their patients [140]. Moreover, primary care providers 
often decide whether or not to refer pati ents to specialists. Therefore, physicians in 
specialities such as hepatology need to understand other physician ' perspectives on 
HCV so that treatment concerns can be adequately addressed, allowing fo r more patients 
to receive treatment [ 140]. 
Pathways of care fo r pati ents diagnosed with HCV were examined by Irving, 
Smith et al. [ 16 1]. The impetus for the study came about because it was reported that only 
55% of patients diagnosed with positi ve anti-HCV were refetTed to a specialist clinic for 
follow up tests [ 162]. The study set out to examine fa ilures to identify, refer, and manage 
patients with chronic HCV. More specifically, drop out rates at all stages of the 
management pathway were examined, as well as reasons for non-refetTal of patients with 
anti-HCV positive te ts to specialty care fac il iti es [ 16 1 ]. The study detenn ined that less 
than 50% of anti-HCV positive patients were referred to a speciali st treatment facili ty 
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[ 161]. Therefore, recommendations were made for all anti-HCY positive patients to be 
referred to specialists for fUiiher management. The one exception for this referral is 
patients who are anti-HCY positive but HCV RNA negative, and this circumstance 
occurs in approximately 20% of people with HCV because of spontaneous clearance of 
HCV. The tudy revealed that there i a need for "innovative multidisciplinary 
approaches" to manage the numerous medical conditions and social i sues in which many 
"real world" HCV patients have. FUithermore, by identifying the reasons for patient 
discontinuation of care, treatment strategies can be implemented to increase patient 
advancement into treatment. 
2.6.2 Management of HCV Infection: Specialist Centres or General Practice? 
There are many complex challenges when providing treatment to patients living 
with HCY. In most cases patients are refeJTed to specialists, such a a hepatologist, in 
order to receive treatment [ 163]. Dusheiko [ 163 ], argues that hepatologi t have a strong 
understanding of the complex nature of the disease and are therefore able to provide 
excellent care to minimise the morbidity of the disease. 
Dusheiko states that HCY care hould remain in a specialist centre in order to 
avoid treatment fai lure through delay and to minimise unnecessary treatment for tho e 
who do not progress to chronic disease. Furthennore, many aspects of managing patients 
with HCV involve experienced clinical interpretation of liver biopsies and for the 
physician to be able to detem1ine the trajectory of the disease in a chronically infected 
patient. Specialist also oversee development of the guidelines for the management of 
HCV care, including the National Institute of Health and European Association for the 
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Study of the Liver guidelines. Moreover, hepatologists also monitor patients' response to 
therapy and any complications that they might have such as resistance, relapse or non-
response. Hepatologists are at the forefront of providing care to HCV patients. They play 
an essential role in the diagnosis and management ofHCC and have also begun to 
manage co-infections with HJV and HCV (or HBV). 
Despite the pivotal role the hepatologist plays in managing HCV care, many 
factors appear to indicate that care should also be provided by non-specialist centre due 
to the large proportion of people living with HCV [ 164]. Brown, JL [164] refutes 
Dusheiko by stating that clinical guidelines have been distributed to all 
gastroenterologists in the United Kingdom and diagnostic tests are avai lable to them as 
well. Consequentl y, the high prevalence of HCV demonstrates that care must become 
more widespread and allow for general practitioners (GPs) to be able to diagnose and 
treat the disease. GPs should fami liarize themselves with ome of the major 
contraindications of the treatment. Moreover, it is vital for GPs to be aware of their 
practice population. For example, if a patient comes to them with abnonnal liver enzyme 
levels but no known risk factors, the physician should have an understanding of the 
patient's indigenous place of birth, drug use history, blood product hi tories so that they 
can help identify patients at-risk for HCV. FU1ihem1ore, it is important for GP to have 
effective communication channels with specialists centres in order to provide up-to-date 
informat ion about HCV to their patients in addition to having access to specialty care 
when needed [9]. 
GPs have a crucial role in the overal l care and management of HCV patients. 
People li ving with HCV may be uncetiain about the virus, methods of transmission, and 
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the fact that it is a silent, on-going infection. Consequently, GPs need to act as "gate-
keepers" of information to inform their patients of the risks and curTent treatment regimes 
available [9]. The treatment ofHCV lies in both the specialty and non-specialty fields. In 
order for this to work, there must be efficient communication between the physicians to 
secure effective management and care ofHCY patients. 
47 
CHAPTER3 RESEARCH DESIGN AND METHODS 
3.1 Methodology 
This quantitative research study used a questionnaire to gain insight about the HCV 
treatment services that exist in Canada. The following sections give an overview of the 
approach that was taken, as well as the methodology of developing the questionnaire that 
was used in the study. 
3.1.2 Surveys 
Surveys are essential tools in health services research in that they provide 
information on knowledge, attitudes, and patterns of care of practicing physicians. 
Physician surveys tend to have an average response rate of 54%, which is 13% lower than 
surveys administered to non-phy ician groups [ 165]. Physicians receive numerous 
questionnaires to complete and often have little time to devote to filling them out. The 
main reasons that have been found for physicians not being able to complete surveys are 
that they were too busy with other work or that the survey got lost in a pile of paper 
[ 166]. It is worth paying attention to phy ician low response rates because physicians 
have a vital role in service planning and provision [ 167]. 
A low response rate can adversely affect a study because of potential non-
response bias. Non-response bias is the effect of a set of respondents who refu e or 
choose not to patiicipate in research. Non-response bias is affected by two factors: the 
percentage of the sample not responding and the degree to which non-responders ditfer 
from the study population [ 167]. Responders and non-responder can be compared in 
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tem1s of demographic differences and other characteristics; however, this cannot assist in 
detetmining if the survey responses are in fact representative of the sampling frame being 
evaluated. 
The proposed study employed variou survey techniques in order to reduce the 
effect of non-response. The "Tailored Design Method" developed by Dillman [ 168] has 
five major components of survey design and admi nistration: ( I) enclosure of a token, 
prepaid, financial incentive; (2) design of a respondent friendly questionnaire (short 
questionnaire with closed ended questions); (3) use of four contact by first class mail 
and one additional special contact (e.g. telephone call); (4) enclosure of a retum envelope 
w ith first clas stamp; and (5) addition of elements that increase personalization, such as 
a thank you card. [ 168]. The five components combined will help to achieve a higher 
respon e rate, however, the use of financial incentives has consi tently been found to be 
the most effective [ 169]. 
Specific survey methods that are able to increase response rates have been 
identified. These include: ( 1) monetary incentives; (2) short questionnaires; (3) 
personalized que tionnaires and letters; ( 4) coloured ink; (5) recorded delivery; (6) use of 
stamped retum envelope ; (7) first class post; (8) contacting participants before sending 
questionnaires; (9) origin of questionnaire12 [ 170]. Furthem1ore, evidence shows that 
using an actual stamp on the retum envelope as opposed to a business repl y stamp 
envelope can increase response rates [168]. It is difficult for many people to throw away 
12 University questionnaires are more likely to be retumed than questionnaires from other sources, such as 
commercia l organisations 
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something that has monetary value so they are therefore more compelled to send the 
questionnaire back. 
Respon e rate are also affected by the urvey mode selected for the study. 
Various studies have indicated that when physicians were offered the choice of four 
response modes- mail, internet, phone and fax- the majority chose to respond to the mail 
mode survey [ 169]. Mixed-mode surveys that allow respondents to be surveyed by 
interview, mail questionnaires, telephone or internet can also help overcome the 
difficulties of obtaining adequate response rates rather than using a single method. 
The components of the "Tai lored De ign Method" can drastically increase the 
cost of a study. The use of prepaid financial incentives, certified mail, telephone calls, 
stamps on return envelopes, and multiple contacts require a compatible budget. In 
contrast, it is important to employ these techniques because the response rates received 
from a study directly affects the study's validity. In effect, it is important to achieve 
response rates that are able to demonstrate that the results from the study do not merely 
reflect a biased- ub sample of the population [ 169]. 
3.2 Methods 
Using the methodology described above, a cross-sectional postal survey 
questionnaire was conducted that included a selection of the recommended methods used 
to increase response rates. Due to the financial constraints of the study, on ly two mail 
outs could be undertaken. The following sections are comprised of the methods that were 
used to can·y out the survey-questionnaire. The survey was administered using the 
following instruments: a pre-notification letter (Appendix A); a survey package 
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containing a cover letter (Appendix B), the survey-questionnaire (Appendix C), and a 
thank-you card (Appendix D); and follow up telephone call (Appendix E). 
3.2.1 Survey Development 
The 14-page questionnaire (Appendix C) used in this study was adapted from 
research conducted by Parkes, Roderick et al. 2006 [ 159] and included items designed to 
assess the workload, configuration and care processes of services in Canada available to 
manage patients living with HCV. The questionnaire was directed at specialists 
(hepatologists, gastroenterologists, infectious disease specialists) in order to evaluate 
their understanding of concepts regarding diagnosis, refetnl practices, access to tests, 
barriers to treatment, treatment eligibility/ineligibility, HCV care management, and drug 
prescribing regimes. 
The survey was distributed to members of the Atlantic Interdisciplinary Research 
Network: Social and Behavioural Issues in Hepatitis C and HJV/AIDS, as well as the 
National Canadian Research Training Program in Hepatitis C for comments and 
suggestions. The survey was then modified based on their feedback . Dillman's mail 
survey techniques were adapted for use in this study to create an effective approach to 
delivering the survey to respondents [168]. 
3.2.2 Target Population 
Practitioners most familiar with management of HCV infection were selected for 
an investigative study ofHCV service provision (i.e. patterns ofhealthcare delivery, 
refetTals, coordinated care teams) in Canada. These specialists were found in the 
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Canadian Medical Directory (CMD) [2] under the titles of hepatologist, infectious disease 
specialist and gastroenterologist. The reason for selecting this populatio n was because 
these pecialists can be deemed the leaders who provide in ight and recommendations 
that most influence the management and care of patients with HCV in their communities. 
It is imperative to note that the treatment of HCV patients can include member of 
a comprehensive care clinic, which can be made up of hepatologists, psychologists, 
psychiatrist , infectious disease speciali st , immunologists, nurse practitioners, and drug 
and alcohol addiction counsellors. ln a essing the treatment provided to people living 
with HCV it would be advantageou to evaluate the entire comprehensive care clinic in 
order to receive a complete account of HCV treatment in Canada. Unfortunately, due to 
time and budget constraints it is unfeasible to contact the entire clinic. Moreover, 
accessing contact lists for the HCV care clinic and all the member as ociated with 
treating people living with HCV would be an arduous task, especiall y if there are no 
common directorie made available. Therefore, it i important to acknowledge that HCV 
health providers constitute a broad group of professions. However, for the ake of this 
study HCV health care providers will represent physicians who provide treatment to 
people living with HCV, such as hepatologist , ga troenterologi t , and infectious di ease 
specialist . 
For the purpose of this study, the sample population was divided into three group 
based on the type of service that the physicians provide to their patients. Respondent 
were asked to choose from the following three categories: (I) no role in the management 
and diagno is of patients with HCV; (2) Diagnosis +/- initial inve tigations fo llowed by 
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refetTal to dedicated HCV service; (3) Provision of a dedicated H V crvice (diagnosi , 
investigation, treatment and follow-up). 
3.2.3 Study Participants 
The total number of physician in the 2006 CMD [2] listed under the designated 
specialties of hepatology, gastroenterology and infectious di ea es was 723. This number 
consisted of 562 English-speaking physicians and 160 French- peaking physicians. The 
CMD li twa examined to verify that it was up to date. Fifty phy ician were randomly 
selected from the list and were called to check that they were till in fact practicing. It 
was found that 46/50 physicians contacted from across Canada arc practicing 
gastroenterologists, hepatologists or infectious disease specialists. Respondents were 
contacted if they met the following inclusion c1iteria and exclusion criteria. 
Inclusion Criteria 
I. Phy ician in one of the designated pecialties: hepatology, gastroenterology, 
infectious diseases a indicated in CMD 
2. Designated as English peaking in the CMD 
Exclusion Criteria 
I. Physicians in pecialtie other than hepatology, gastroenterology, infectiou 
di ea es 
2. Designated as French speaking in the CMD 
3.2.4 Survey-Questionnaire Design and Content 
The survey-questionnaire (Appendix ) consisted of fo ur cctions: 
(I) Health care provider demographics 
(2) Identification of HCV patients 
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(3) H CV treatment 
(4) HCV service configuration 
In general, the que tion fonnat consi ted of closed que tions with multiple choice 
and true/fa[ e answer and took approximately 5- 10 minutes to complete. 
3.2.4.1 Variables 
Data was categorized into three group , ba ed on the type of service provided by 
the physician. The questionnaire started with health care providers having to describe 
their role in the management of patient with H V. They had to elect from three 
descriptions: (I) o role in the management of hepati tis C infection; (2) Providing 
diagnostic and investigative service but not treatment (diagnostic investigative provider-
DIP); (3) Providing diagnostic testing, investigations, treatment and fo llow-up of patient 
(comprehen ive ervice provider-CSP). If re pondents chose the fir t description, they 
did not have to proceed to the other parts of the urvey. They needed to s imply check the 
box stating that they do not provide a role in HCV management, mention the consul tant 
who provides the HCV service, and return the questionnaire. However, if respondents 
chose the other two options they were directed to further questions on designated page 
of the que tionnaire. 
Geographical locations and region were also coded. Region were grouped 
together according to the Natural Resources of Canada website Atlas on Canada [ 17 1 ]. 
The four regions are as follows: (I) Atlantic region: Newfoundland, Nova Scotia, New 
Brunswick, Prince Edward Island ; (2) Central region : Ontario and Quebec; (3) The 
Pra iries: Manitoba, Saskatchewan and Alberta; (4) Western Canada: Briti h Columbia. 
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The ten·ito ri es, Nunavut, orthwest Territories and Yukon were excluded. These regional 
groupings were done to examine whether or not differences could be observed on a 
regional basis a well as a provincial ba i , allowing for a broader sense of HCV services 
in Canada. 
3.2.4.1.1 Demographic Variables 
Respondent who categorized them elve in the DIP or CS P category were then 
classified by age and ex. They were a ked to select from 5 age group (<30, 30-39, 40-
49, 50-59 and 60 or o lder). Respondent had to indicate the size of the community in 
which they practice. They had 4 choices: :S 25,000; > 25,000 but < I 00,000; 100,000 to 
500,000; and 500,000. Respondents al o had to indicate their practice type and could 
select more than one option ( olo practice, multiple-specialty group, academic, other). 
Finally, respondents were asked to describe the population that is be t erved by their 
clinical practice or hospi tal [urban (wholly), urban (predominantl y), mixed urban (more 
urban than rural), mixed rural (more rural than urban), rural (predominantly), rural 
(wholly), other]. 
3.2.4.1.2 Variables for Diagnostic Investigative Providers 
Diagnostic Inve tigative Providers (DIPs) were asked to fill out in fom1at ion 
regarding the management of HCV patient in their practice or hospital. DIPs had to 
indicate the prop01iion of patients diagno ed with HCV who are managed by a selection 
of physicians (hepatologists, gastroenterologists, infectious disea e peeiali st, intemist 
and other). They al o had to indicate how many patients they diagno ed with HCV in 
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2005 (< 10, 10-19,20-29,30-39,40-49, and >50). Moreover, they had to indicate the 
percentage of patients diagnosed and subsequently refeiTed to a pecialist HCV service 
(< 10%, 10-24%,25-49%,50-74%, 75-90%, and >90%). Finally, DIP were asked to state 
if they had acce s to specific tests either in-hou e or external (qualitative PCR, viral load 
measurement, HCV genotyping and pecialist liver histopathol gy). DIP were then 
asked if they ever treat patients with H V and the name of consultant( ) who provide a 
specialist HCV service for their patient population. 
3.2.4.1.3 Variables for Comprehen ive Sea·vice Providers 
The ection for Comprehensive ervice Providers contained all of the above 
infonnation that was filled out by the DIPs in addition to asking about: 
( l) Prevalence of HCV in the respondent' practice 
(2) Referral 
(3) Diagno tic test and coun elling 
(4) Treatment regimens 
(5) Service configuration of practice 
(6) Barrier in the management of patients with HCV. 
CSP were a ked to state the total number of patients with known H V under their 
care and the approximate number of new HCV patients seen in the year 2003 , 2004, 
2005. They could select from four categories of patients (< l 0, I 0- 19, 20-30, and ~40). 
Respondents were also asked the approx imate percentage of new patients who miss 
their initial appointment and could choo e from six categories (0-4%, 5-9%, I 0-24%, 25-
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49%, 50-74%, ~75%). They were also asked the percentage of time that they spend on 
clinical management of HCV patients (0-4%, 5-9%, 10-24%, 25-49%, 50-74%, ~75%). 
The source of referrals was also evaluated by asking respondents to indicate how 
many HCV patients came to them already diagnosed (0-4%, 5-9%, I 0-24%, 25-49%, 50-
74%, ~75%). If the initial diagno is was made before referral , CSPs were also asked to 
indicate the approximate percentage of refen·al from the following sources (primary care, 
prison healthcare, drug and alcohol service, hepatology, gastroenterology, infectious 
diseases, internist, and other). Moreover, respondents were asked to indicate the source of 
referral when the respondents them elves made a diagnosis ofHCV (primary care, prison 
healthcare, drug and alcohol service, hepatology, gastroenterology, infectious diseases, 
internist, and other). Furthennore, CSPs were asked to indicate ifthey refer HCV patients 
to colleagues for further management and to state the circumstance in which they do o 
(treatment, follow-up, complex clinical is ues relating to HCV, joint management, 
transplantation, patients desire for a second opinion). 
CSPs were asked to indicate whether or not they have acces to specific diagnostic 
tests, either in-house or external (qualitative PCR, viral load measurement, HCV 
genotyping and specialist liver histopathology) and if counselling ervices are available 
for their patients. 
The section on patient treatment examined the criteria used to determine which 
patients are eligible for treatment (age, gender, genotype, severity of hepatitis, severity of 
fibrosis, history of substance use/abuse, co-morbidities, extrahepatic manifestations 13) 
and whether or not the physicians would offer treatment under pecific circumstances, 
13 An ex trahepatic manifestation means diseases or conditions that affect organs other than tl1e li ver. 
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such as normal ALT, severe hepatitis and patient awaiting transplantation. In addition, 
main reasons for patient ineligibility (i .e. ongoing drug use, ongoing alcohol use, 
psychiatric disorder) were asked. They were also asked to indicate the proportion of new 
patients with HCY seen in 2005 who were eligible for treatment (0-5%, 6-9%, I 0-24%, 
25-49%, 50-74%, 75-89%, 2:90%) and the proportion of eligible patients who actually 
received treatment (0-5%, 6-9%, I 0-24%, 25-49%, 50-74%, 75-89%, 2:90%). 
The pattern of drug prescribing (i.e. interferon alone, pegylated interferon & 
ribavirin in combination) was also asked, as well as criteria used to end treatment. 
Respondents were asked to indicate if they follow dose reduction guide! ines and the 
proportion of patients who receive a pre-treatment li ver biopsy. A section on refusal of 
treatment a ked the reasons given by eligible patients who refuse therapy (i.e. cost, 
inconvenient to start treatment due to work pressures, lack of concern over future). In 
addition, another question asked respondents to indicate the percentage of patients who 
stop treatment prematurely (0-5%, 6-9%, I 0-24%, 25-49%, 50-74%, 75-89%, 2:90%) and 
their reasons for stopping. (i.e. no response to treatment, loss to follow up, side effects). 
The section on service configuration of the practice asked respondents to indicate if 
they have a coordinated management strategy for HCV patients and if they work in a 
multidisciplinary team setting. If they did work in a team setting they were then a ked to 
select the members from a list of discipline (i.e. internist, radiologi t, specialist nurse 
etc.). 
The final section examined ban·iers to providing care, and respondents had to rank 
specific barriers (i.e. biopsy waiting times, taffing capacity, patient non-ttendance) and 
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then write any additional comments. Moreover, CSPs had to indicate the number of 
patients awaiti ng treatment, appointments, funding decisions, and investigations. 
3.2.5 Survey Method 
The following sections outline the implementation of the survey-questionnaire. 
Beginning with the fonnat used to distribute the survey, followed by the return of the 
surveys and follow-up. 
3.2.5.1 Questionnaire Distribution 
The distribution and follow up proceeded in the following format: 
(I) Pre-notification letter mailed out (Appendix A) 
(2) Survey packaged mailed out: Cover letter (Appendix B); Survey-
questionnaire (Appendix C); Thank you card (Appendix D) 
(3) Follow-up telephone call to a random sample of physicians who had not 
returned questionnaire: Telephone sc1ipt (Appendix ). 
Surveys were mailed to 562 physicians at their sites of practice. A pre-notification 
letter (Appendix A) was sent a week before the package in order to notify the respondents 
of the study. The first letter, which introduced the participants to the study, was mailed 
out on January 25th 2007. The letter contained infonnation o utlining the objectives of the 
study as well a the affinnation of confidentiality and how infonned consent is obtained. 
This was followed by the survey package (Appendix Band C), which was sent out on 
January 3 151 2007. Questionnaires were given code numbers and mailed to each potential 
respondent with a covering letter and bu iness reply stamped return envelope or a real 
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stamped return envelope. Half of the survey packages contained bu iness reply tamps 
and the other half received real postage stamps on the return envelopes to evaluate 
whether or not the response rate would be affected by the type of reply stamp placed on 
the envelope. The package also included a thank you card (Appendix 0 ). 
3.2.5.2 Questionnaire Return 
Participants were asked to place the completed questionnaire in a pre-addressed, pre-
paid envelope. Anonymity was maintained because each survey was coded. Upon receipt 
of completed questionnaires, the geographical area and specialty of the physician was 
written on the front page and the code number was removed and replaced wi th a new 
number. 
3.2.5.3 Telephone Follow-Up 
T he telephone fo llow-up call d id not prove to be an effective method of contacting 
physicians to remind them to fill out the questionnaire. Onl y 2 of the physicians who 
were contacted later returned the questionnaire. Numerous obstacles arose when phoning: 
( I) the phone number provided by the CMD was a hospital and not a direct I ine to the 
physician; (2) mail boxes were often fu ll so messages could not be left; (3) physicians 
were rarely spoken to directly. It is fo r this reason that so few physicians received a 
fo llow-up call. Moreover, the lag time from when the letter was sent out to the time the 
follow-up call s were made was too long, which possibly led for the q uestionnaire to be 
misplaced, lost, or forgotten. 
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3.3 Data Entry and Analysis 
The data was fir t entered into Micro oft Access Ver ion 11.0. A copy of the 
survey was created in Access and once all of the surveys were entered, the database was 
analyzed using the Statistical Package for Social Sciences (SPSS) Version 15.0 for 
Windows. Descriptive statistics including frequency tables and cross-tabulations were 
used to analyse data. Data was cleaned by coding answers. For instance, when 
respondents provided answers to open-ended questions the an wers were coded to allow 
for an overall view of the respondents' answers. This occulTed when participants had the 
option of providing a different response from the list provided. In this case, like-
responses were grouped together. For example, pa1iicipants were asked in question 23 to 
state which source provided the initial HCV diagnosis if it was made prior to referral. 
Participants could choose from a list of responses that included such disciplines a 
primary care, prison healthcare, and hepatology. If a source was not listed, pa1iicipants 
could specify the other source such as, psychiatric hospital. These other sources were 
then coded by combining the specified sources into group so that they could be given a 
coding number and then analysed. 
3.4 Ethical Considerations 
Permission to conduct the study was granted by the Human Investigation 
Committee (HIC) of the Faculty of Medicine, Memorial University. When conducting 
any f01m of research involving humans the Tri-Council Policy Statement: Ethical 
Conduct .for Research Involving Humans (TCPS) must be applied. The TCPS ensures 
6 1 
respect for human dignity. The welfare and integrity of participants are of primary 
concem during the research process. Respect for privacy and confidentiality was 
employed throughout the study. This was add res ed in terms of the protection toward the 
access, control and dissemination of personal information of research subjects. The 
surveys are kept in a locked storage area and access is limited. Moreover, computer files 
are password protected. In addition, the requirement of free and informed consent was 
put into effect so that all participants were fully aware of the intentions of the study. 
Completion of the questionnaire was taken to indicate individual consent. The study was 
conducted by policies on ethics outlined by HIC. An HIC application for the study was 
submitted in September 2006 and approved on January 2211d 2007 (Appendix F). 
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CHAPTER4: RESULTS 
4.1 Introduction 
The following ection pre ent detailed results obtained from the analysi of data 
collected by the national survey of Hepatitis ervices in Canada, 2006. There pondent 
were 222 physicians selected from the CMD under the specialties of gastroenterology, 
infectious diseases, and hepatology. French peaking physicians were excluded from the 
survey. 
4.2 Response Rate 
From the initi al list of 562 physicians, 25 were deemed ineligible for the study 
due to the following reasons: returned to sender (e.g. moved, does not treat HCV 
patients) (n= 17), emai led to state they do not treat HCV patient (n=5) and retired (n=3). 
A random sample of36 physicians who had not yet returned the que tionnaire recei ed 
follow-up telephone calls a month and a half after the survey packag was distributed. f 
the physicians who were phoned, 9 were deemed ineligible for the study a follow : do 
not treat H V patients (n=4); no time to fill out survey (n= l) ; moved (n=2); on holiday 
(n= l); on maternity leave (n= l). In total , 34 physicians were deemed ineligible from the 
initial list of 562. Therefore, of the eligible 528 physicians, 222 returned completed 
questionnaire (42% re ponse rate). There was no significant difference observed 
between there pondents who received a bu ine s reply stamped envelope and an 
envelope with a real postage stamp. Almo t halfofthe re pondent who replied (50.9%) 
had a real stamp, and just less than half ( 49.1 %) had a busines reply stamp. 
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Forty-three percent of respondents provided a comprehensive service (included treatment 
and follow-up) , 33% provided a diagnostic and investigative service (followed by referral 
to dedicated HCV service), and 24% had no role in the management and diagnosis of 
people with HCV. Table 2 presents the response rates by specialty. 
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Table 2: Response rates & management role in the ca•·e of patients with chronic 
Hepatitis C by specialty 
Number Number in 
in initial survey after 
survey correcting for 
ineligible 
respondents 
N (%) 
GI 330 (58 .7) 308 (58.3) 
10 172 (30.6) 162 (30.7) 
Hepatology 60 (10.7) 58 (11.0) 
Total 562 (1 00) 528(100) 
DlP= diagnostic & investigative provider 
CS P= comprehensive service provider 
G I =G astroen tero I o gist 
ID=Infectious disease specialist 
Overall No role DIP 
responding N (%) N (%) 
N (%total) 
11 9 (38.6) 31 (58.5) 35 (47.9) 
78 (48.1) 21 (39.6) 35 (47.9) 
25(43. 1) I (1 .9) 3 (4. 1) 
222 (42.0) 53 (1 00) 73 (I 00) 
The medical practice of the respondents was approximately 54% ( 119/222) 
gastroenterologists, 35% infectious disease specialists and II % hepatologists. 
CSP 
N (%) 
53 (55 .2) 
22 (22.9) 
21(21.9) 
96 (100) 
Coordinated Service Providers (CSPs) made up of 84% (21 /25) of the hepatologists who 
responded, 28% of infectious disease specialists, and 45% of gastroenterologists. The 
majority of infectious disease specialists provided no role or a diagno tic investigative 
provider (D IP) service (72%). Slightly over half of the gastroenterologists provided no 
role or a DIP service (55%). Infectious disease specialists had the highest response rate of 
48%, followed by hepatologists (43%) and gastroenterologists (39%); however, the 
differences were not statistically significant, (x2=3.93, d. f=2, P=0.1374) (refer to Table 
2). 
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4.3 Socio-demographic Characteristics 
The distribution of the socio-demographic characteristic for the DIPs and CSPs 
are summarized in Table 3. 
Table 3: Socio-demographic characte.-istics of Dl Ps (N=73) and CSPs (N=95) 
Variable Total DIPs (N=73) Total CSPs (N=95) 
Age group 
<30 0 0 
30-39 30.1% (22) 15.8% (15) 
40-49 39.7% (29) 42.1% (40) 
50-59 2 1.9% ( 16) 29.5% (28) 
60+ 8.2% (6) 12.6% (12) 
Missing data 0 1% (I) 
Sex 
Male 66.7% (48) 82.1% (78) 
Female 33.3% (24) 17.9% (17) 
Missing data I% (1) 1% (1) 
Years in Practice 
<5 2 1.4% (15) 7.4% (7) 
5-9 17. 1%( 12) 18.9% (18) 
10-19 34.3% (24) 38.9% (37) 
~ 20 27.1%(19) 34.7% (33) 
Missing data 4% (3) 1% (1) 
Size of community where they 
practice 
:s 25,000 0 2.1 %(2) 
>25,000 but < I 00,000 4.1% (3) 6.3% (6) 
I 00,000 to 500,000 17.8% (13) 44.2% (42) 
> 500,000 78. 1% (57) 47.4% (45) 
Missing data 0 1% (1) 
Practice Type* 
Solo practice I I 44 
Multiple-specialty group II 16 
Academic 54 40 
Other I 2 
*Respondents could mdtcate more than one practtce type 
Multiple-specialty group= Patients managed by a team (i.e. HCY nurse and gastroenterologist) that 
coordinates care 
Academic= University based 
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The age group most represented by DIPs and CSPs was 40-49 years. The 
distribution of males versus females for DIPs was 66.7% and 33 .3% respectively, and for 
CSPs the distribution was 82.1 % males and 17.9% females. DIPs were mostly practicing 
in districts of over 500,000 people and the majority had between I 0-20 years in practice. 
Moreover, the majority of DIPs were practicing in academic centres. 
Overall, the CSPs had between I 0-20 years of practice and were practicing in 
communities with 100,000 to more than 500,000 people. In addition, CSPs were 
primarily practicing in academic centres or in solo practice. 
4.4 Management of HCV Patients by Diagnostic Investigative Providers 
The majority of the populations being served by the clinical practice or hospital of 
DIPs was predominantly urban followed by mixed urban (more urban than rural) (refer to 
Figure 2). Patients diagnosed with HCV in the practice or hospital served by DIPs arc 
managed as follows : Overall DIP indicated that gastroenterologists, infectious disease 
specialists and internists manage HCV patients less than 50% of the time. 
Question 7 of the survey asked DIPs to estimate the prop01tions of patients 
diagnosed with HCV in their practices who were managed by different types of 
specialists (hepatologists, gastroenterologists, infectious disease peciali t). Just over half 
ofthe DIPs indicated that hepatologi ts managed HCV patients more than 50% of the 
time and 20% indicated that gastroenterologists managed patients more than 50% of the 
time. This demonstrates that HCV patient are for the most part managed by 
hepatologist , fo llowed by gastroenterologists (refer to Table 4). 
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Figure 2: Distribution of the population served by DIP clinical practice or hospital 
Pm1icipants were asked to indicate approximately how many patients they 
diagnosed with HCV in 2005. Mo t DIPs cared for a small number of patient with HCV 
infection, with 72% diagnosing less than 10 patients with HCV (2005) and 92% 
diagnosing less than 20 patients (refer to Figure 3). Moreover over 90% of the time the 
majority of patients diagnosed with HCV by DIPs are refened to a specialist HCV 
service (refer to Figure 4). 
Table 4: DIPs identification of specialties that manage patients diagnosed with HCV 
Proportion of DIPs indicating which specialties manage HCV patients 
Proportion of Gl Hepatologist lD Internist 
patients (N=69) (N=69) (N=69) (N=67) 
managed(%) 
~50 79.7% 49.3% 89.9% 100% 
>50 20.3% 50.7% 10. 1% 
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Figure 3: Number of patients diagnosed with HCV by DIPs in 2005 - results based on 72 DIP respondents 
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DIPs have access to diagnostics tests either in-house or external (refer to Table 5). 
The maj01ity of DIPs do not treat HCV patients (76%) and Fi!,rure 5 summarises the 
hospital that provide a specialist HCV service to their patients. The majority of DIPs 
(91 %) indicated the name of the hospital to which they refer their patients. 
Table 5: Diagnostic tests available to DIPs 
Percentage of DIPs* with access to diagnostic services 
Service In-house 
Qualitative PCR 52.9% N=70 
Viral load measurement 44.9% N=69 
HCV genotyping 40.6% N=69 
Specialist liver 67.1% N=70 
histopathology 
*Totals can exceed 100% as more than one response 
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Figure 5: Hospitals referred to by DIPS that provide a specialist HCV service to their patients 
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15 
4.5 Management of HCV Patients by Comprehensive Service Providers 
Comprehensive Service Providers were asked to specify the description that best 
fits the population served by their clinical practice/hospital. The majority of the 
populations being served by the clinical practice or hospital of CS P was mixed urban 
(more urban than rural), followed by predominantly urban (refer to Figure 6). 
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Question 18 asked CSPs to indicate the total number of patients with known HCV 
cun·ently under their care. The total estimated prevalent population of patients with HCV 
managed by the responding CSPs was 27, 652 of which 62% were managed by 
hepatologists ( 17,095/27,652), 20% were managed by gastroenterologists (5643/27,652) 
and 18% were managed by infectious disease specialists ( 49 14/27 ,652). The number of 
prevalent patients varied between CSPs, the average number of patients under the care of 
CSPs was approximately 346. At the extremes, nine CSPs managed fewer than 20 cases 
in total and ix CSPs were managing more than I 000 patients in total. 
Table 6 shows the mean number of patients seen by CSPs by specialty. The 
median number of patients under the care of the hepatologists who responded was 900. 
Gastroenterologists had a median number of 134 under their care and infectious disease 
specialists had a median number of259 patients under their care. Furthermore, 60% of 
the CSP respondents (48/80) had over 40 patients under their care (refer to Table 7). The 
infom1ation in Table 7 also reveal s that a hepatologist or infectious disease specialist 
tended to care for more HCY patients than a gastroenterologist (x2=6.09, P=0.0476). 
Table 6: Number of patients with known HCV under the care of CSPs by specialty 
.\ 
N Minimum I Maximum Mean Std. Deviation 
Hepatologist 19 15 4000 899.74 1295.330 
Gastroenterologist 42 3 1200 134.36 224.748 
Infectious disease 19 20 1500 258.63 393.242 
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Table 7: Proportion of CSPs who have over 40 patents with HCV under their 
care by specialty (N=80) 
Number of CSPs who see Number of CSPs who see 
less than 40 Qatient mo•·e than 40 Qatients Total 
<40 >40 
Specialty Gastroenterology 22 20 (52%) 
Infectious diseases 6 13 (68%) 
l-lepatology 4 15 (79%) 
Total 32 48 
Figure 7 shows the number of HCV patients under the care ofCSPs divided by 
province. The province with the mo t CSP who care for over 40 patient i Ontario, 
followed by British Columbia, Alberta, Quebec, ew Brunswick, Saskatchewan, ova 
Scotia and Newfoundland. 
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Figure 7: Number of patients with known I-ICY under the care of CSPs by province 
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Between 2003-2005 there is a gradual increasing trend in the number of patients 
seen by CSPs (refer Table 8). In 2003, 51. 1% of CSPs saw over 20 patients, which 
increased to 57.3% in 2004, and finally to 59.4% in 2005. 
Table 8: App•·oximate percentage of new patients seen by CSPs from 2003-2005 
Year 
Number of new 2003 2004 2005 
patients 
< JO 23 .3% 16.9% 15.4% 
10-19 25.6% 25.8% 25.3% 
20-30 12.2% 15.7% 16.5% 
>40 38.9% 4 1.6% 42.9% 
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The approximate percentage of new patients who miss their initi al out-patient 
appointment was indicated to be between 10-24%, by 44% of the CS P respondents (refer 
to Figure 8). 
50 
40 
10 
0-4% N=20 5-9% N=21 10-24% N=41 25-49% N=9 50-74% N=2 
Percentage of new patients who miss their initial out-patient appointment 
Figure 8: Approximate percentage of new patients who miss their initial appointment 
75 
Figure 9 reveals that the majority of CSPs spend between 5-24% of their time 
managing patients with HCV. 
40 
0-4% 5-9% 10-24% 25-49% 50-74% >75% 
Percentage of time spent by CSPs on the clinical management of patients with HCV 
Figure 9: Percentage of time spent by CSPs on the clinical management of patients with HCV 
76 
4.5.1 Identification and Referral of HCV Patients Under the Care of CSPs 
At the time of referral, half of the responding CSPs indicated that the diagnosi of 
HCV infection was already made over 75% of the time (refer to Figure I 0). 
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Figure 10: Proportion of patients referred to CSPs already diagnosed with HCV 
Of patients referred with an establi hed diagnosis, 60% of CS Ps indicated that the 
majority of refetTals came from primary care the majority of the time (80%). 
Gastroenterology and prison health care were the two other major clinical pecialties in 
which patients were referred to CS Ps already diagno ed; II % of re ponding CS Ps 
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indicated that they received patients already diagnosed over I 0% of the time from p1ison 
health care, and l 0% of responding CSPs indicated that they receive patients already 
diagnosed from gastroenterology over I 0% of the time. Of those refetTals where the CSP 
establi shed the diagno is of HCV, 63% of CS Ps indicated that the majority of patients 
came from primary care over 80% of the time. Thus, the main source ofrefen·al to CSPs 
where the diagnosis was made before referral and where the CS P made the diagnosis is 
the same. Both referrals come from a primary care source. Therefore, patients being 
refe1Ted to CS Ps from primary care have a 50% likelihood of already being diagnosed 
with HCV. 
The majority of responding CSPs (80%) indicated that they refer patients to 
colleagues for further opinion or management. The main reasons for referral arc as 
follows (refer to Table 9): 
Table 9: Reasons for CSPs to refer HCV patients to colleagues (N=77) 
Reasons for referral 
Patient wants a second o inion 
Percentage of CSPs referring to 
colleagues 
5% 
3% 
60% 
44% 
83% 
33% 
The main reasons that CS P refer their HCV patients to colleagues are for 
transplantation, complex issues related to HCV and for joint management. In addition, 
CSPs respondents noted that they also refer patients to their colleagues for endoscopy, 
clinical trials andre-treatment. 
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4.5.2 Diagnostic Tests and Services Available for the Management of HCV Patients 
The majority of the responding CSP had access to diagnostic test external to 
their practice or hospital (refer to Table 1 0). In contrast, more DIPs had access to such 
tests in-house than externally (see Tabl e 5). 
The avai labi lity of counsell ing and support service to CSPs for the treatment of 
HCV patients is shown in Figure 11. Access to an HCV special ist for post-test 
counselling and support was avai lable to 46% of responding CS P . In addition, 20% of 
CSPs had access to general coun elling services, 12% had an HCV nurse, 3% had a nurse 
who was sponsored by a pha1maceutical company to coun el and support patients, and 
16% had no access to any counsell ing services. 
Table tO: Diagnostic tests available to CSPs 
Percentage of CSPs* with access to diagnostic services 
Service In-house External 
Qualitative PCR 40% 65% 
Viral load measurement 27% 76% 
HCV genotyping 26% 77% 
Specialist liver 50% 56% 
histopathology 
*Totals can exceed I 00% as more than one response 
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4.5.3 Drug Treatment of HCV Patients 
The majority of responding CSPs indicated that between 25-74% of new patient 
in their clinical practice were eligible for treatment in 2005 (refer to Figure 12). 
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Figure 12: Proportion of new patients with HCV eligible for treatment in 2005 - based on reports from 
93 CSPs. 
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Participants were asked to state the prop01iion of their H V patient e ligible for 
treatment who actually received treatment in 2005 (Figure 13). Over half of the CS Ps 
(57%) indicated that at least 50% of their eli g ible patients received treatment. Thirty-
three percent reported that over 75% of eligi ble patients were treated and 12% reported 
that over 90% of elig ible patients received treatment. Figure 14 displays the percentage of 
patients who received treatment in the context of clinical trials in 2005. The majority of 
patients were not treated in the context of clinical trials with 58% of the responding CSP 
indicating that onl y between 0-5% of their patients received treatment in the fom1 of a 
clinical ttial. 
Table II shows the factors used to detennine eligibility for treatment of patient 
with HCY. Over 90% of responding CSPs used severity of fibrosis and co-morbidities as 
criteria to determine eligibility. Other major factors considered are age (87%) and 
severity of hepatitis (86%). In addition, some respondents also indicated that they 
consider the fo llowing when determining treatment eligibility: insurance coverage, HCV 
RNA level , prior treatment, psychosocial is ues and compliance. 
Virtually a ll of the responding CSPs definitely offered treatment to patients with 
moderate or evere hepatitis, extrahepatic manifestations, and Child-Pugh A (refer to 
Table II). However, CSPs were less likely to treat patients with Child-Pugh C ( 19%) or 
if patients are awaiting transplantation (37%). The Child-Pugh score i used to assess the 
prognosis of chronic liver disease, mainl y cirrhosis. T he score of' A' refers to well-
compensated disease, 'B'- a s ignifi cant functional compromise, and ' '-decompensated 
disease. 
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Table 11: Eligibility for anti-viral treatment of patients with HCV 
Question Choices Percentage of 
CSPs saying 
yes 
Which of the following Age (N=92) 87% 
criteria do you consider in Sex (N=91) 9% 
determining eligibility for HCV genotype (N=93) 68% 
treatment? Severity of hepatitis (N=94) 86% 
Severity of fibrosis (N=93) 9 1 % 
Hi tory of substance use/abuse (N=91) 71 % 
Co-morbidities (N=93) 99% 
Extrahepatic manifestations (N=91) 86% 
Would you likely offer Mild hepatiti on biopsy (N=89) 73% 
treatment to patients with onnal ALT (N=88) 60% 
the following scenarios who With extrahepatic manifestation (N=94) 98% 
had no other Moderate hepatitis (N=94) 96% 
contraindications'? Severe hepatiti s (N=94) 97% 
Cirrhosis 
Child-Pugh* A (N=95) 95% 
Child-Pugh B (N=92) 65% 
Child-Pugh C (N=92) 19% 
Pati ent awaiting transpl antation (N=92) 37% 
N= Number of respondents 
*Child-Pugh score is used to assess the prognosis of chronic liver disease 
Responding CSPs indicated that the main reasons for patient ineligibili ty for 
treatment were ongoing illi cit drug misuse, ongoing alcohol misuse, and psychiatric 
disorder. The main reasons that CSPs indicated fo r patient refusal of treatment were 
concern over drug reactions and inconvenience due to work pressures (refer to Table 12). 
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Table 12: Reasons for patient ineligibility and refusal of treatment (N=95) 
Question Choices Percentage of 
CSPs saying 
ves 
What are the main reasons Refusal to modify chaotic 46% 
for patients' refusal of li festyle 
treatment? 
Lack of belief in treatment 27% 
effectiveness 
Concern over adverse drug 84% 
reactions 
Inconvenient to start treatment 70% 
due to work pressures 
Lack of concern over future 13% 
Cost 50% 
Desire for pregnancy within 18 20% 
months 
The scenarios desc1ibed in Table 13 were difficult to answer for many of the 
respondents, as there was not enough detail provided for each individual case. Moreover, 
8% of respondents indicated that they would on ly provide treatment for certain scenarios 
if there was also co-care with a psychiatrist. 
The majority of responding CSPs (94%) indicated that they would provide 
treatment to an ex-injection drug user who is stable on substitution therapy. Respondent 
were then asked to indicate how long the patient would have to be stable on substitution. 
Most CSPs (91 %) indicated the patient would have to be on sub titution treatment for 
more than 6 months, 4% of CSPs indicated the patients should be on substitution 
treatment for 3 months, and 4 % ofCS Ps indicated that there was no limit to the length of 
time. 
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Table 13: Treatment scenarios of people with moderate/severe cht·onic HCV 
Question Scenarios Percentage of 
CSPs saying yes 
Which of the following Continuing injection drug user who regularly uses 21 % (N=91) 
patients with needle exchange 
moderate/severe chronic 
HCV are likely to receive Ex-injecting drug user stable on ubstitution 94% (N=92) 
treatment in your clinical treatment 
practice? 
Heavy alcohol consumer in regular employment 14% (N=92) 
17 year o ld person with haemophilia: Would you do 25% (N=85) 
a liver biopsy? 
38 year old person with haemophilia without biopsy 91 % (N=85) 
Person currently in treatment for psychiatric 
problems 61 % (N=86) 
Person with history of attempted suicide 49% (N=84) 
Whilst using drugs of addiction 43% (N=90) 
In context of previous non drug related 52% (N=84) 
psychiatric problems 
Person with current diagnosis of depression related 78% (N=92) 
to HCV infection 
Person with current diagnosis of depression 58% (N=91) 
Person with past history of depression 97% (N=92) 
Person with poorly controlled diabetes 40% (N=94) 
Person with angina 34% (N=93) 
Only 2 1% of CSPs would provide treatment to a continuing injection drug user 
who regularly uses a needle exchange program. The CSP specialty most likely to treat a 
current lOU were infectious disease speciali ts, of whom 40% reported that they would . 
This was followed by 24% ofhepatologists and 12% of gastroenterologists. ln reality, the 
scenarios in Table 13 are often more complex than what is described. Therefore, a yes or 
no answer cannot always be given to the underlying situation. 
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Effectively, all of the responding CS Ps (99%) used pegylated interferon and 
ribavirin to treat patients with HCV. 67% of CSPs indicated that they do not use printed 
guidelines for dose reduction and stopping treatment. Of the CSPs who stated that they 
do follow guidelines (33%), 73% of responding CSPs follow the drug company standards 
and 18% follow the Canadian Association for the Study of the Liver guidelines. 
A pre-treatment liver biopsy was perf01med on HCV patients less than 50% of the 
time by just over half of responding CSPs (56%). Only 22% of responding CSPs stated 
that they perfonn a pre-treatment liver biopsy over 75% of the time. 
Just over half ofresponding CSPs (55%) reported that between 10-24% of 
patients stop treatment prematurely (both patients and professional initiated) . The 
majority of the responding CSPs provided the following reasons for stopping treatment 
prematurely (refer to Table 14). The maj01ity of responding CSPs (74%) selected no 
response to treatment as the number one reason for stopping treatment prematurely, 
followed by 6 1% indicating that ide effects (patient initiated) wa the econd reason. 
Table 14: Reasons for stopping treatment prematurely 
Question Reasons ranked 1-4 
What are the reasons for I) No response to treatment 
stopping treatment 2) Side effects (patient 
prematurely? initiated) 
3) Side effects (professional 
initiated) 
4) Loss to fo llow up 
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4.5.4 Patient Management 
Co-ordinated management strategies for the treatment of patients with HCV were 
reported by CSPs (refer to Table 15). The most common fom1al collaboration between 
CSPs and other services was the link formed between the CSP and primary care, which 
was indicated by 30% of responding CSPs. Thi was followed by 22% of responding 
CSP indicating that they had a link with a nurse practitioner and drug and alcohol 
addictions services. In addition, ofthe 7% of responding CSPs who stated that they have 
other links to coordinated management, 50% indicated that they have a HCV nurse, while 
other CSPs indicated that they had links with HlV co-care and a social worker, both 17% 
respectively. Only 2% of CSP respondents from Table 15 de cribed their coordinated 
management strategy used for providing care to their HCV patients. The answers 
provided indicated that of the CSPs, 32% have a multidisciplinary cl inic, 28% have close 
communication with the refetTing physician and nurse practi tioner, 16% have their 
patients managed by an HCV nurse, 12% are coordinated with the prison system, 8% 
have a nurse sponsored by a pham1aceutical company who managed their patients, and 
4% are in close communication with a methadone clinic. 
Table 15: Coordinated management of HCV patients 
Question Choices Percentage of CSPs saying 
yes 
Do you have a coordinated Nurse practitioner 22% (N=87) 
management strategy for Primary care 30% (N=86) 
patients with HCV linking Prison healthcare 15% (N=85) 
secondary/tertiary care to: Drugs and alcohol services 22% (N=85) 
Homeless 4% (N=85) 
8 
The maj rity of responding CSP (61 %) had a multidi ciplinary team 
coordinating the management of HCV. The composition of the team varied but most 
commonly included at least a consultant from the lead clinical specialty, and specialist 
nurse. Other teams were more complex and also had gastroenterologists, infectious 
diseases specialists and hepatologist (refer to Table 16). Of the 23% of SP who 
indicated that there were other members of the multidisciplinary team not provided in the 
selection choices, 50% stated that they also coordinate care with a p ychologi t, 21% 
have access to a ocial worker, 14% have acccs to a psychiatri t, and a hematologist 
and speciali t denti twas indicated by 7% of responding CSPs rc pcctivcly. 
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Table 16: Membership of multidisciplinary team to coordinate management of 
HCV patients (N=57) 
Membership of multidisciplinary team Percentage of CSPs saying yes 
Gastroentero logist 56% 
Internist 2% 
Family Phys ician 16% 
Hepatologist 40% 
Specialist nurse 97% 
Histopatho logi t 30% 
Radiologist 18% 
Infectious disease clinician 49% 
Community drug and a lcoho l addictions 12% 
counsello r representative 
2% 
Care professional from homeless age ncy 
2% 
Genito urinary medic ine c linician 
2% 
Community intravenous drug users care 
professional 
2% 
Patient representative 
2% 
Community dentist 
4.5.5 Barriers to Providing a High Quality Service for Patients with HCV 
91 % of CSPs reported barri ers in the management of patients with HCV. T he 
main factors are shown in Table 17. Funding, patient non-attendance and staffing 
capacity were the most common. 
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Table 17: Barriers to providing a high quality service 
Reason Agree/strongly Unsure Disagree/Strongly 
agree 0/o disagree % 
Clinic waiting time 43 5 52 
for initial referral 
Biopsy waiting 15 3 83 
times 
Staffing capacity 46 3 51 
Staffing skill mix 17 10 73 
Funding for 69 8 24 
treatment 
Patient refusal 58 16 26 
Patient non- 67 17 16 
attendance 
Patient 34 32 34 
identification 
Table 18 displays the answers provided by CSPs who reported other ba1Tiers to 
care for patient with HCY. The main barriers indicated were lack of supp01t and 
resource , such as access to HCV nurse specialists and funding from government and 
phannacare, followed by education of other health care workers and referral at the fami ly 
physician level. 
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Table 18: Additional comments regarding barriers in the management of patients 
with Hep C 
Barriers Percent of CSPs indicating barrier 
Lack of support: 
funding(government/pharmacare); 
resources (Rep C nurse) 
Education of other health care workers 
and refer·ral at family physician level 
Cost of treatment 
Time-consuming process 
Lack of coordinated multidisciplinary 
team 
Ineligible because of lifestyle issues 
(alcohol, drug use) 
Prison system not involved in 
coordination of HCV therapy 
Not enough physicians treating HCV 
patients 
Psychosocial issues (financial, 
employment, side-effects from 
treatment) 
35% 
17% 
14% 
10% 
7% 
7% 
3% 
3% 
3% 
Additional comments made by CSPs with regards to aspects of care for patients 
with HCV are summarised as follows. One CSP indicated that it is common practice fo r 
them to test for HCV RN A PC R at week four to detect ifthere was a rapid virological 
response to therapy. T his is in addition to the customary HCV RNA PCR test at week 12. 
Other ban·iers to care involved treatment delay and long waiting lists. It was mentioned 
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that a large number of patients are referred to academic centres and not to their local 
physicians, thus creating a lengthier proce s for patients to initiate therapy. It was also 
indicated that the efficiency of the clinic was due to a dedicated care team and the 
presence of a nur e practitioner in the organisation and follow-up of treatment. 
4.6 Geographical Distribution of Services 
The distributions of Engl ish speaking phy icians in the specialties of 
gastroenterology, hepatology and infectious diseases who are li ted in the CMD are 
hown in Figure 15. The provinces with the mallest number of H V health care 
provider are Prince Edward Island (n= I), ewfoundland (n=7) and cw Brunswick 
(n=7). In contra t, the provinces with the largest number HCV health care providers are 
Ontario (n= 255), Alberta (97), and British Columbia (n=78). Figure 16 displays the 
distribution of HCV health care provider who responded to the urvey. Canada's 
population by province is shown in Figure 17, which reveal that the di tribution of 
specialist who are HCV healthcare providers fo llows a similar di tribution to the 
population of each individual province. The only province that does not follow this 
pattem is lberta which shows that there are more HCV peciali ts in lberta even 
though it has a smaller population than Briti h Columbia. 
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The majority of responding HCV healthcare providers from New Brunswick 
(I 00%), Saskatchewan, (I 00%), and Newfoundland (83%) indicated that they were 
CSPs. Respondents from Ontario and British Columbia reported that 43% were CSPs and 
74% were CSPs respectively. The provinces that reported the smallest number ofCSPs 
were Manitoba (9%), Alberta (22%), Nova Scotia (25%), and Quebec (28%) (refer to 
Figure 18). 
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Provinces 
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Figure 18: Distribution of roles in management of HCV patients by province 
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Figure 19 illustrates the distribution of HCV management roles across Canada. 
The survey results revealed that Western Canada has the greatest proportion ofCSPs 
(74%), followed by Atlantic Canada (57%), Central Canada ( 41 %) and the Prairies 
(22%). 
I have nn role in the 
management and diagm1sis 
Atlantic region Central region Prairies Western region 
Regional group 
Figure 19: Distribution of roles in management of HCV patients by region 
Atlantic Region=NL, NS, NB, PEl 
Centra l Region=QC, ON 
Prairies=MB, SK, AB 
Western region= BC 
Diagnosis+/- initial 
investigations 
Provisions of a dedicated 
Hcp C service 
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The Prairies was the region that had the most CSPs (75%) who indicated that they 
saw over 40 patients in 2005. This was followed by 54% ofCSPs in Western Canada, 
followed by 34% in Central Canada and 16% in Atlantic Canada (refer to Figure 20). 
._ 
0 
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Figure 20: umber of new HCV patients een by SPs by r egion in 2005 
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The region that has the mo t CS P working in a multidi ciplinary team setting i 
the Prairies (92%). Western Canada ha the econd highest amount (73%), fo llowed by 
Atlantic Canada (50%), and Central Canada (48%) (refer to Figure 2 1 ). 
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The province that had the highest percentage of CSPs most likely to treat a current 
IOU who uses a needle exchange on a regular basis was Albe1ta, with 50% of responding 
CSPs stating that they would provide treatment to a patient in this scenario (refer to 
Figure 22). This was followed by 33% of CSPs in Nova Scotia, 28% in Ontario, 20% in 
Quebec, and 12% in British Columbia. 
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CHAPTER 5: DISCUSSION 
5.1 Introduction 
This survey involved a national repre entative sample of phy icians who manage 
patients with H V. A completed questionnaire was received from 222 of the eligible 528 
physicians urveyed, resulting in a respon e rate of 42%. This wa higher than the 
response rate of 33% obtained in an American study on primary care physician' 
knowledge and practice patterns concerning H V [ 152]. 
The tudy revealed variation in structure and configuration at all tages of the 
patient care pathway, such as size of practice community, number of patients, and type of 
care service provided. 
5.2 Roles in the Management of HCV Patients 
Variation was observed in the physician specialties (hepatology, gastroenterology 
and infectious di ea es) that provided a coordinated service to H V patients. Even 
though there were fewer physicians in the field of hepatology, 85% of hepatologists who 
responded to the urvey designated them elves as a CSP. In contra t, only 45% of 
gastroenterologi t and 28% of infectious disease specialists reported that they were a 
CSP. 
Physicians who indicated that they provide a diagnostic investigative service 
stated that their patients are managed by hepatologists 50% of the time, followed by 
gastroenterologi ts 20% of the time. DIP tended to look after very few H V patients. 
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For instance, 72% of D!Ps diagnosed le than I 0 patients, and more than 90% of DIP 
referred their HCV patients to a specialist H V service. 
5.3 Comprehensive Service Providers and HCV Patient Caa·e 
The di tribution of HCV health care providers throughout anada corre ponded 
to the population distribution of each province. For instance, Ontario has the highest 
population with more than 12 million people [ 172] and also has the greatest number of 
HCV health care pro iders (infectiou disease specialists, hepatologi ts, 
gastroenterologi t ) (n=255) li ted in the MD [2]. [n contra t, P I ha the smallest 
population in Canada with 139,000 people, and on ly one HCV health care provider wa 
identified in the MD [2]. 
5.3.1 Provision of HCV care by Comprehensive Service Provide.-s 
CSP tended to practice in large mixed-urban/urban communiti with 
populations ranging between 100,000 to over 500,000 people. Despite the fact that there 
are fewer English peaking hepatologi ts practicing in Canada (n=60), compared to 
ga troenterologi t (n=330) and infectiou di ease pecialist (n= 172), this urvey found 
that the majority of HCV patients are cared for by hepatologi ts. It wa found that a large 
number of gastroenterologists (n= 11 9) were only caring for an average of 134 HCV 
patients. Thi is quite a difference compared to the 78 infectious di ease specialists (who 
cared for an average of 259 patient and the 25 hepatologists (who cared for an average of 
900 patient ). Thi distribution of patients cared for by HCV care providers is likely due 
to the fact that the majority of HCV patients are referred to hepatology because 
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hepatologists generally have the most experience in the care and treatment of HCV 
patients. 
5.3.2 Management of HCV Patients 
Very few C Ps (46%) had full accc to a specialist for po t-tc t counselling and 
support. However, 66% ofCS Ps had either access to a specialist for post-test counselling 
and/or acce s to general counselling services. It hould be noted that 15% of CSPs made 
a comment that a H V nurse, either pon ored by a pharmaceutical company or hired by 
the clinic, conducted counselling and support. This demonstrate that some clinics have a 
trained nurse working directly with them to assess and monitor HCV patient , whereas 
others do not. 
Despite the fact that 6 1% of re ponding CSPs repOiied that they work with a 
multidisciplinary team, only 2% ofC Ps acknowledged that they have a coordinated 
management trategy involving connection to areas such a primary care, drug and 
alcohol services and nur e practitioners. Furthetmore, only 13 ofthc SP who had 
coordinated management strategies indicated that they had link with prison health care, 
and only 3 CSP had links to homeles agencie . Due to the complexity of the health and 
psycho ocial i ues of HCV patients, it i vital for HCV phy ician to have a coordinated 
team approach with other areas, such a social services and drug and alcohol coun elling, 
in order to provide comprehensive care to their patients. It is necessary for HCV health 
care providers to as ess the population need in their area, which wi ll primarily be driven 
by the local IOU prevalence (including people with HCV in the pri on system). 
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5.3.3 Drug Treatment and Barriers 
This survey found that very few HCV -infected patients under the care of CSPs are 
receiving anti-viral therapy. For instance, 43% of CSPs indicated that less than 50% of 
their patients eligible for treatment actual ly received treatment. In Canada, health-care 
costs a sociated with HCV are estimated at $500 million/year, and are expected to 
increase to over $1 bi Ilion a year this decade [ 173]. In order for these projections to be 
changed, a systematic program for the treatment of HCV infection must be put in place. 
Barriers to care were identified, which revealed difficulties experienced by HCV 
health care provider in coping with the pre ent burden of patients in the healthcare 
system. The variation observed from this survey could create an inequity in the provision 
of care for people li ving with HCV. Thus, thi s survey provides a base for future planning 
of services and health care pathways that can address the current inequalities. 
The majority of CSPs (over 65%) identified funding for treatment and patient 
non-attendance as the two main batTier to care. As the number of patients with advanced 
liver disease due to HCV increases, these barriers will become even more apparent with 
major repercussions for health care provider in tenns of recruiting, training and funding 
specialized staff. 
5.3.4 Distribution of Comprehensive Service Providers by Province and Region 
The distribution of CSPs across Canada varies, and may help identify an inequity 
in HCV care provision. For example, the majority of HCV providers in Saskatchewan, 
ew Brunswick, and ewfoundland identified themselves as CSPs, whereas other 
provinces such as Alberta, Nova Scotia and Quebec stated that less than 30% of their 
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HCV providers were CSPs. Overall, when CSPs are examined by region it wa revealed 
that Western Canada has the highest percentage of CSPs (74%) and the Prairies have the 
lowest percentage of CSPs (22%). 
An interesting observation is that even though the Pra iri es have the least amount 
of CS Ps per region, they have the highest number of HCV providers working in a 
multidisciplinary setting (92%). T hi s may be the reason why the Prai ries had the highe t 
percentage ofCSPs (75%) who saw over 40 patients in 2005. 
5.3.5 Provision of Treatment to Current Injection Drug Users 
Over 70% of new cases of HCY infection per year involve IDUs [5). CuiTently, 
there is no consensus on how to offer them medical care. It is important to note that the 
majority of CSPs who responded to thi s survey indicated that they would not provide 
treatment to a cun-ent injection drug user who uses a needle exchange on a regular basis. 
CSPs within A B (50%) and NS (33%) were most likely to provide treatment to cunent 
ID Us. This is despite the fact that there is growing evidence that IDUs have had simliar 
compliance and treatment response rates when compared to non-IDUs [84, 86, 87, 90-
92]. Moreover, it is sugge ted that adherence to antiviral therapy will be increased if 
patients are enro ll ed in multidi sciplinary programs where there is coll aboration between 
areas such as addi ction counselling and a hepato logi t in order to allow for thorough 
patient fo llow-up by the comprehensive care team [86). The future burden of HCY is 
quite alanning and in order for patients to receive the care that they need, a more 
effective way to plan health care strategies and resource allocation is requi red. 
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5.4 Limitations of the Study 
There were a number of limitations to this study. Even though the response rate 
was higher than other studies, such as the American study on primary care phy ician's 
knowledge and practice patterns concerning HCV (which had a re pon e rate of 33% 
[ 152]), it wa till fairly low at only 42%. Moreover, the data obtained from the survey 
was self-report and made up of the respondents' estimates of the 1-1 V -management 
conditions in their practice and their own behaviours, which are likely to be imprecise. 
Furthermore, it i po sible that phy icians overestimated their perfom1ance due to social 
desirability bia . ocial desirability bia occur when there i a predi po ition to fill out a 
questionnaire when responses reflect the respondent in a favourable light, according to 
perceived social norms and values. 
It i a lso po sible that phy icians who responded to the urvey had more 
favourable HCV-related practice pattern . Consequently, !-ICY-management practices 
could be wor e than what was documented. T hu , the validity of elf-report needs 
consideration in interpreting the findings. 
A major limitation was the fact that the survey was onl y sent out to English 
speaking H V health care provider . Thi notably reduced the number of e lig ible 
participant from 72 1 to 562 and therefore did not provide a complete examination of 
HCV health care serv ice and pathway throughout Canada (and Quebec in particular) . 
Furthennore, the Territories (Nunavut, Yukon, N01ih West TetTitorie ) were excluded 
from the study, limiting the examination of geographical variation .. 
In addition, health care providers that do not return the survey may create 
selection bias called non-response bias. on-response bias is the effect of a et of 
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respondents who refuse or choose not to participate in research, which can make it very 
difficult to assess the results properly. As well , the response received from the survey 
might have differed from the actual practice. 
The Canadian Medical Directory [2] was the professional list u ed to sample 
participants. The list was fairly up-to-date (2006), but any inaccuracies may have led to 
some physicians not receiving the survey. FUtihennore, physicians may have been 
defined inaccurately or identified under multiple subspecialties within CMD, and 
therefore some physicians that treat HCV patients might not have been surveyed if they 
were not categorized properly. It would have been helpful to have surveyed a random 
sample of family physicians because they play a key role in the diagnosis and 
identification of HCV patients. However, this was beyond the scope of the project due to 
time and budget constraints. 
The survey tool itself was a limitation because some questions were too vague to 
allow respondents to provide a clear answer. Consequently, the collection tool may have 
been ambiguous at times and therefore unable to assess the issues being examined in a 
concise f01mat. 
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CHAPTER 6: CONCLUSIONS AND IMPLICATIONS 
6.1 Introduction 
Thi survey evaluated how individuals with HCV are identifi d, referred, 
diagnosed, and treated within Canada. Re pondents revealed that there is variation across 
Canada as to how patients are refetTed at the DIP and CSP level, as well as the type of 
care patients receive, whether it is in a multidisciplinary or academic etting. The mai n 
barriers to care were funding for treatment and patient non-attendance. Nevetiheless, 
based on the multidisciplinary team settings and comprehensive ervice revealed by 
survey respondents, opportunities to model fom1s of health care strategies were reported 
to be quite successful. Moreover, urgent investment by government is needed to improve 
the identification, funding, and management of people with HCV in order to help 
decrease the chances of HCV -related deaths and the burden of the disease in the future. 
6.2 How can services identified by this study be improved to meet the needs of HCV 
patients? 
The distribution of CSPs by province corresponded to the population distribution 
across Canada. This reveals that there is a trend associated with the population of each 
province and the number ofHCV health care provders that they have, with more HCV 
health care providers working in province with higher populations of people. Despite 
this fact, only 65% of the estimated cases of HCV in Canada have been identified [ 4]; 
regardless ofthe number ofphyscians available to provide HCV treatment, there needs to 
be a more effective method of providing HCV care. This has an opp01iunity to occur 
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through the management of regional I-ICY networks and support by a national 
infon11ation system which will allow more patients with I-ICY to receive comprehensive 
treatment. 
Fwihem1ore, thi study clearly identifie a need for impro ed treatment acces of 
people who inject drugs (the p1imary cau e of HCV transmission). There needs to be a 
call for more walk-in clinics for HCV carrier with addictions, such as the one created in 
Oakland, Califomia in I 998 [80]. Thi clinic wa created to reduce specific barriers to 
providing H V treatment and improve diagnosis of HCY in les - table drug users. The 
focus of the clinic is on peer support and provide educational session about HCV and 
the entire diagnosis process [80]. The clinic has a care team con isting of an infectious 
disease speciali st, a nur e, a psychiatric specialist and an administrator who provides 
educational services [80]. Therefore, all the needs of the patients can be met effectively. 
In Canada, there i a similar clinic able to provide the type of care outlined in the 
Oakland, Califomia model. In Vancouver, British Columbia the Pender Commuity 
Health Centre is a multidisciplinary program where the initial medical evaluation is 
asses ed by family phy icians and addiction specialists in deliberation with the infectious 
disea e con ultant [I 74]. If a deci ion ha been made to proceed with treatment, 
nursing staff then administer weekly IF injections under direct ob ervation. They 
monitor adherence, and report any adver c effects or other event to the physicians. In 
addition, trained counselling staff are available on-site to provide supp01i. HCV support 
groups, monitored by an addictions coun ellor, also meet once a week to discuss 
treatment progre s, ide-effects and challenges [I 74]. The Pender ommunity Health 
Centre should be u ed as a model for HCV care in other cities aero the country in order 
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to provide interprofessional care that will allow HCV patients to receive treatment in a 
supportive environment. 
The move towards a well-developed coordinated pathway of patient care would 
allow for more effective communication between the health and social disciplines. This 
would enable patients to have the support they need (i .e. hou ing, transportation, 
addiction counselling) while being monitored on HCV treatment. The majority of 
patients with HCV also have other medical conditions and consequently i sue such as 
addiction must also be addressed. This would give patients the support that they need in 
order to make it through the entire course of antiviral therapy. A treatment team model 
would ideally include frequent psychiatric ymptom monitoring and provision of care by 
primary care physicians, hepatologists, nurse practitioners, mental health professionals 
and substance abuse professionals [34). This fotm of a coordinated care clinic would 
meet the needs of the patient while also allowing for continuity of care amongst the 
health discipline . This would ideally increase the number of patients undergoing a 
successful regimen of antiviral therapy, and thu decrease the medical and economic 
burden ofHCV in Canada. 
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APPENDIX A : PRE-NOTIFICATION LETTER 
Recipients 
Address 
Dear Dr. 
Divi ion of ommunity 
Health & Humanities 
Faculty of Medicine 
Memorial University 
300 Prince Philip Dr. 
t.John', L AIB3Y6 
Within the next few days, you will receive a request to complete a questionnaire. I am 
mailing it to you in an effort to learn more about Hepatitis C viru (HCV) treatment in 
Canada. 
The aim of the study is to investigate the identification, testing, referral , selection for 
treatment, and follow-up ofHCV positive patients. Through the questionnaire I hope to 
identify regional variations in HCV practice, which has implications for improving HCV 
care and the quality of life for people li ving with HCV. Results derived from this study 
will be able to identify regional variations in HCY practice, which has implications for 
improving HCY care. 
The infonnation data that I will need will be treated a confidential and kept in the faculty 
at Memorial Univer ty in secure storage. Access to the questionnaires i r stricted to my 
supervisor and my elf. T he survey wi ll be anonymous and completion of the 
questionnaire i voluntary. lfyou decide that you no longer want to be involved in this 
study you are free to withdraw at any time. Returning the complete que tionnaire 
indicates you have been infonned and will be considered your con ent to participate in 
the study. The Human Investigation Committee at Memorial Univer ity has approved the 
study. 
I would greatly appreciate your taking the few minutes necessary to complete and return 
your questionnaire. Please feel free to contact me [(709) 749-9697 or 
angcliquemylc (? ,gmail.com] or my supervi or, Dr. Peter Wang [(709) 777-857 1 or 
pwang@mun.ca] a you wish 
T hank you in advance for your he lp. 
Sincerely, 
Angelique Myles 
Principal Investigator 
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APPENDIX 8 : COVER L ETT ER IN SURVEY PACKAGE 
Recipients 
Address 
Dear Dr. 
Division of Community 
Health & Humanities 
Faculty of Medicine 
Memoria l Universi ty 
300 Prince Phil ip Or. 
St. John's, NL A lB 3V6 
My name is Angelique Myles and I am a Masters student in Community Health at Memoria l 
University under the supervision of Dr. Peter Wang. I am writing to invite you to participate in 
research in the form of a questionnaire. 
My Ma ters Proj ect is entitled " An Examination of Regional Variation in T reating Hepatitis C 
Patients in Canada." Specifically, it is assessing how physicians are provid ing treatment to people 
living with Hepatitis Virus (HCV). The aim of the study is to inve ligate the identification, 
testing, referra l, selection for treatment, and fo llow-up of HCV positive patients. Thi in formation 
is of impo rtance to you because it will establish baseline in formation to plan future services for 
people living with HCV. Through the que tionnaire I hope to identify regional variat ions in I-ICY 
practice, which has implications for improving I-IC Y care and the qua lity of life for people living 
w ith HCV. 
The questionnaire should take about 5 minutes to complete . Enclosed is a pre-paid envelope for 
the return of the questi01maire. I would greatly appreciate it if you would complete the 
questio nnaire within one week of receiving it. In order for information from the tudy to be truly 
representative, it is essential that each person in the sample return their questionna ire. r will be 
making a fo llow-up telephone call in two weeks time to remind you to complete the questionnaire 
if you have not a lready done so. 
T his is an anonymous survey and the info rmation data that I will need wi ll be treated as 
confidentia l and kept in the faculty at M emoria l Universty in secure storage. Acce s to the 
questionnaires is restricted to my supervisor and myself. Completion of the questionnai re is 
vo luntary. If you decide that you no long r want to be involved in this study you are free to 
w ithdraw at any time. 
Completion of the questionnaire indicates you have been info rmed and wi ll be considered your 
consent to partic ipate in the study. Upon receipt, the questionnaire will be coded and your name 
and address will be kept separate from it. When you return the questionnai re, you do not give up 
your legal rights. Researchers or agenc ie involved in this research study still have their legal and 
professional respons ibilities. If you would li ke to obtain a summary of there ults of thi research 
I would be happy to send you copy upon completion of the study 
P lease feel free to contact me [(709) 749-9697 or angcliquemylcs(algmail.com] or my supervisor, 
Dr. Peter Wang [(709) 777-857 1 o r pwangCa1mun.ca] as you w ish. In addition, please ask your 
secretary to e-ma il me a convenient time at which I can call your office. 
S incerely, 
Angelique Myles Principal Investigator 
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APPENDIX C: SURVEY-QUESTIONNAIRE 
National Study of Hepatitis C Services 
ID 
Please complete the fo llowing details: Your repli es wi ll be treated in strict confidence 
Your role in management of Hepatitis C 
1. What is your role in the management of Patients with Hepatitis 
C? 
Circle answer that most applies to your practice. 
a) I have no role in the management and diagnosis of patients 
with Hepatitis C. 
Please answer the fo llowing question and return questionnaire in envelope provided . 
.... It would be very helpful to this national survey if you could state in the space 
below the name of the consultant who provides a specialist Hepatitis C service for your 
patient population. 
Hospital __________________________ _ 
Thank you very much for your help. 
Please return the questionnaire in the stamped addressed ~nvelope 
provided. 
b) Diagnosis +/- initial investigations, followed by referral to a 
dedicated Hepatitis C service*. 
Please answer Q2-12 on pages 2-4 and return questionnaire in 
envelope provided. 
c) Provision of a dedicated Hepatitis C service*. 
Please proceed directly to Q13 on page 5. 
* includes diagnosis, investigation, treatment, & fo llow-up 
urvey adapted from Parke , J., ct a l. , Variation in Hepatitis C services may lead to inequity o.fhealth-c:are pro1•ision: a 
survey o.fthe organisation and de/ive1y o.fservices in the United Kingdom. BMC Publ ic Health, 2006. 6(3). 
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.... If you selected ( Q 1 b), please complete the fo llowing que tion. 
2. Health Care Provider Demographics 
Age 
<30 0 
30-39 0 
40-49 0 
50-59 0 
60 or older 0 
3. Sex maleO 
4. Size of community where you practice 
5. 
::; 25,000 0 
> 25,000 but < I 00,000 0 
I 00,000 to 500,000 0 
> 500,000 0 
Practice Type (check all that apply) 
Solo practice 
Multiple-specia lty group 
Academic 
Other 
femaleO 
0 
0 
0 
0 
Years in 
practice 
<5 0 
5-9 0 
10-19 0 
~ 20 0 
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Your Hospital 
6. Please specify the description that best fits the population served by your 
clinical practice/hospital. 
Urban (wholly) 
Urban (predominantly) 
Mixed urban (more urban than rural) 
Mixed rural (more rural than urban) 
Rural (predominantly) 
Rural (wholly) 
Other please specify 
7. What proportions of patients diagnosed with Hepatitis C in your 
practice/hospital are managed by the foUowing? 
Hepatologist * % 
Gastroenterologist % 
lnfectiou disease specialist % 
Internist ~o 
Other- please specify __________ _ 
*(hepatologist = those doctors whose substantive work is in liver disease) 
8. Approximately how many patients with Hepatitis C did you diagnose in 
2005? 
<10 
10-19 
20-29 
30-39 
40-49 
>50 
9. What percentage of these patients did you refer to a specialist Hepatitis C 
service? 
< 10% 
I 0-24% 
25-49% 
50-74% 
75-90% 
>90 
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Diagnosis 
10. Do you have access to the following tests? 
Service In bouse External Number of tests 
(yes/no) (yes/no) •·equested by 
you on average 
per month 
Qualitative PCR 
Viral load measurement 
HCV genotyping 
Specialist liver 
histopathology 
11. Do you EVER treat patients with Hepatitis C? Yes/No 
12. It would be very helpful to this nat ional survey if you could state in the pace below the 
name of the consultant(s) who provide(s) a specia list Hepatitis C service for your pat ient 
population. 
Hospita l ________________________ _ 
Thank you very much for your help. 
Please return the questionnaire in the stamped addressed 
envelope provided. 
Your replies will be treated in strict confidence. 
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.... If you provide a dedicated Hepatitis C service (Qlc), please 
complete the following questions. 
13. Health Care Provider Demographics 
Age 
<30 0 
30-39 0 
40-49 0 
50-59 0 
60 or older 0 
14. Sex maleO 
15. Size of community where you practice 
16. 
s 25,000 0 
> 25,000 but < I 00,000 0 
I 00,000 to 500,000 0 
> 500,000 0 
Practice Type (check all that apply) 
Solo practice 
Multiple-specia lty group 
Academic 
Other 
femaleO 
0 
0 
0 
0 
Years in 
practice 
<5 0 
5-9 0 
10- 19 0 
2: 20 0 
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Your Hospital 
l7. Please specify the description that best fits the population se•·ved by your clinical 
practice/hospital. 
Urban (wholly) 
Urban (predominantly) 
Mixed urban (more urban than rural) 
Mixed rura l (more rural than urban) 
Rura l (predominantly) 
Rura l (whol ly) 
Other please specify _______________ _ 
Prevalence of Hepatitis C in your practice 
18. What is the total number of patients with known hepatitis C currently under your 
care? 
19. What was the approximate number of new HCV patients seen by you in each of the 
following years? 
2003 2004 2005 
<10 
10-19 
20-30 
>40 
20. What is the approximate percentage of new patients who default from their initial 
out-patient appointment? 
0-4% 
5-9% 
10-24% 
25-49% 
50-74% 
>75% 
21. What percentage of your time is spent on the clinical management of patients with 
llepatitis C? 
0-4% 
5-9% 
10-24% 
25-49% 
50-74% 
>75% 
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Referrals 
Source of referrals 
The ./ollowing questions apply both to those patients referred to you in 2005 with a 
problem subsequently diagnosed as Hepatitis AND also those referred to you with an 
established diagnosis o.fhepatilis C. 
22. What proportion of patients referred to you came with a diagno is of Hepatitis C? 
0-4% 
5-9% 
10-24% 
25-49% 
50-74% 
>75% 
Unsure 
23. Where the initial diagnosis of hepatitis C was made before referral, please give the 
approximate percentage of referrals from each of these sources. 
Primary care % 
Prison healthcare % 
Drug and Alcohol service % 
Hepatology % 
Gastroenterology % 
Infectious diseases % 
lntemi t % 
Other please specify ________________ _ 
24. In those patients in whom YOU make the diagnosis of Hepatitis C, please indicate 
the source of referral with approximate proportions. 
Primary care % 
Prison healthcarc % 
Drug and Alcohol ervice % 
Gastroenterology % 
Infectious diseases % 
Intern ist 
Hepatology 
Unsure 
% 
% 
Other - plea e pecify _______________ _ 
Management of patients w ith Hepatiti s C 
25. Do you ever r·efer patients with Hepatitis C to colleagues for further opinion or 
management? 
Yes/No 
I f Yes 
26. In what circumstances do you refer to colleagues? 
For treatment 
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For fo llow up 
For complex clinica l issues relating to Hepati tis C 
For joint management e.g. with psychiatry 
For transplantation 
Patient wants a econd opinion 
Other - please specify __________________ _ 
Diagnosis 
27. Do you have the following investigative tests a vailable? 
Ser vice In house External Number of tests 
(yes/no) (yes/no) per month 
Qualitative PC R 
Viral load measurement 
HCV genotyping 
Specialist liver 
histopathology 
C ounselling 
28. What counselling and support services a re available in your pr-actice/hospital for 
patients with Hepatitis C? 
Access to HCY specialist (any profession/grade) for post-test counselling and support 
Access to general counselling service 
No access to counselling services 
Other - please specify __________ ________ _ 
T reatment 
Initia ting treatment 
29. Which of the following criteria do you consider in determining eligibility for 
treatment? 
Age 
Sex 
HCV Genotype 
Severity of hepatitis 
Severity of fibrosis 
History of substance use/abuse 
Co-morbidities 
Extrahepatic manifestations 
Yes/No 
Yes/No 
Yes/No 
Yes/No 
Yes/No 
Yes o 
Yes/ o 
Yes o 
Other - please specify _____________ _ 
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30. Would you be likely to offer treatment to a patient with the following scenarios who 
had no additional contraindications: 
Mild hepatiti s on b iop y Yes/No 
Normal AL T Y e /No 
W ith extrahepatic mani fe tations 
Moderate hepatitis 
Severe hepatiti 
Cirrhosis 
Child- Pugh A 
Child- Pugh B 
Child - Pugh C 
Patient awaiting transplantation 
Yes/No 
Yes/ o 
Yes o 
Ye o 
Yes/ o 
Yes/No 
Yes/No 
31. Which of the following patients with moderate/severe Chronic Hepatitis C are likely 
to receive treatment in your clinical practice? Please tick all that apply. 
Continuing injecting drug user who regularly use needle exchange Ye o 
Ex-injecting drug user stable on sub titution therapy Yes o 
(I ryes, for how long must they have been stable on ubsti t ut ion?) 
Heavy alcoho l consumer in regular employment 
17 year o ld per on with haemophi lia would you do a liver biopsy? 
38 year o ld person with haemophilia without biop y 
Person currently in treatment for psychiatric problems 
Persons with past history of suicide 
w hilst using drugs of addiction 
in context of previous non drug related p ychia tric problems 
Person with current diagnosis of depre sion related to HCV infection 
Person with current diagnosis of depression 
Person with pa t history of depression 
Person with poorly controlled diabetes 
Person with angina 
Yes/No 
Yes/No 
Yes o 
Ye o 
Yes o 
Yes/No 
Yes/No 
Yes/No 
Yes o 
Yes o 
Yes o 
Yes/No 
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32. What proportion of new patients with Hepatitis C seen in your clinical practice in 
2005 were ELIGIBLE for treatment? 
0-5% 
6-9% 
10-24% 
25-49% 
50-74% 
75 -89% 
>90% 
33. What were the main reasons for patients' ineligibility? Please rank 1-6 in 
descending order of importance. 
Psychiatric disorder 
Cardiovascular disease 
Ongoing illicit drug misuse 
Ongo ing a lcoho l misuse 
Other medical co-morbidities 
HlV co-infection 
Other (Please 
specify), _________________ _ 
34. What proportion of your patients with Hepatitis C eligible for tt·eatment received 
treatment in 2005? 
0-5% 
6-9% 
10-24% 
25-49% 
50-74% 
75 -89% 
>90% 
35. How many of these have been treated in the context of clinical trials in 2005? 
0-5% 
6-9% 
10-24% 
25-49% 
50-74% 
75 -89% 
>90% 
36. What antiviral drug regimes do you currently use to treat patients with Hepatitis C? 
Please tick all that apply. 
Interferon alpha alone 
Interferon a lpha and ribavirin 
Pegylated interferon alone 
Pegylated interferon and ribavarin 
Amantadine 
Other- please specify __________________ _ 
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Stopping treatment 
37. Which of the following criteria do you use to end treatment? Please tick all 
appropriate boxes. 
Therapy HCV PCR+ Persistently •·aised Lack of~ 2 log 
regime ALT reduction in vi.-al 
load 
3 months 6 months 3 months 6 months 3 months 6months 
IFN 
alone 
IFN/R 
Peg IFN 
Peg 
IFN/R 
38. Do you have printed guidelines for dose reduction and stopping therapy? 
Yes/No 
lfyes, we would be grateful for a copy to be enclosed with your returned questionnai re. 
39. In what percentage of patients do you perform a pre treatment liver biopsy? 
0-5% 
6-9% 
10-24% 
25-49% 
50-74% 
75-89% 
>90% 
Refusal of treatment 
40. What reasons do eligible patients who refuse treatment give? Please tick all that 
apply. 
Refusal to modify chaotic li festy le 
Lack of belief in treatment effectiveness 
Concem over adver e drug reactions 
Inconvenient to start treatment due to work pressures 
Lack of concem over future 
Cost 
Desire for pregnancy within 18 months 
Other - please 
speci~-------------------------------------
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41. What percentage of patients stop treatment prematurely (both patient and 
professional initiated)? 
0-5% 
6-9% 
10-24% 
25-49% 
50-74% 
75 -89% 
>90% 
42. What are the reasons for stopping treatment prematurely'? Please rank 1-5 in 
descending order of importance. 
No response to treatment 
Side effects (patient initiated) 
Side effects (professional initiated) 
Loss to fol low up 
Other- please specify __________ ________ _ 
Service configuration 
Liaison 
43. Do you have a coordinated management strategy for patients with IICV linking 
secondary/tertiary care to: 
Family urse Practitioner reservations 
Primmy care 
Prison hea lthcare 
Drugs and alcohol services 
1-Iomeles 
Yes/No 
Yes/No 
Yes!No 
Yc f o 
Yes o 
Other- plea c sp ci fy _______________ _ 
If Yes to any of the above 
44. Please state briefly a summary of the strategy or attach documentation if available. 
135 
r------------------------------------------------------------------------------------------
45. Do you have a multidisciplinary team that coordinates the management of 
Hepatitis C in your area? 
Yes/No/Unsure 
If Yes: 
Please indicate the membership of the group. Tick a ll that apply. 
Gastroentero logist 
Internist 
Famjly Phys ician 
Hepatologist 
Specialist nurse 
Histopathologist 
Radiologist 
Infectious disease clinician 
Community Drug and Alcohol Team representative 
Care professional from homeless agency 
Genito urinary medicine clinic ian 
Community Intravenous drug users care profess ional 
Patient representative 
Community dentist 
Other - please specify _____________________ _ 
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Barriers and blockage in the management of patients with Hepatitis C 
46. Are the•·e any identified barriers in the management of patients with Hepatitis C? 
Yes/No 
lfYes: 
47. Please indicate your response to each of the given statements describing possible 
barriers to care for patients with Hepatitis C. 
Strongly Agree Unsure Disagree Strongly 
agree disagree 
Clinic waiting 
time for initial 
referral 
Biopsy waiting 
times 
Staffing 
capacity 
Staffing 
skillmix 
Funding for 
treatment 
Patient refusal 
Patient non 
attendance 
Patient 
identification 
Other - please 
specify 
Please write any add itiona l comments regarding barriers in the management of patients with 
Hepati tis C below. 
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48. Please give the approximate numbers of your patients with Hepatitis C who are 
currently 
Awaiting out patient appo intment 
Awaiting investigations 
Awaiting funding decisions 
Awaiting treatment 
Other points in the health/social care systems where patients arc waiting 
(please specify), _________________ _ 
49. If you would like to make any further comments on aspects of care for patients with 
Hepatitis C, please use the space below. 
Thank you very much indeed for taking the time to .fill this questionnaire. 
It will make a substantial contribution to the completeness of the national 
needs assessment of Hepatitis C in Canada and provide information with 
which to plan future services. 
Please return the questionnaire in the stamped addressed envelope 
provided. 
Your replies will be treated in strict confidence. 
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APPENDIX D: THANK YOU CARD 
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APPENDIX E: TELEPHONE SCRIPT 
Hello can I speak to Dr. xxx? 
Hi Dr. xxx, my name is Angelique Myles and I am a Masters student at Memorial 
University. 1 am calling to inform you that last week a questionna ire about Hepatitis C 
treatment was mailed to you. 
If you have already completed and returned the questionnaire to me, please accept 
my sincere thanks. If you have not, please continue filling out the questionnaire and 
returning it. I am especially grateful for your help because I believe that your 
response will be useful to understanding potential barriers to referral and treatment 
of Hepatitis C patients. 
If you did not receive a questionnair·e, or if it was misplaced, please let me know and 
I will send you another copy in the mail today. 
Thank you for your time and patience. 
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APPENDIX F: ETHICS APPROVAL 
January 17, 2007 
Reference #06.189 
Ms. Angeli que My l s 
C/o Dr. P. Wang 
Division of Community H ealth & Humanities 
Memorial Univ rsity of N ewfoundland 
Dear Ms. Myles: 
This will acknowl dge your correspondence dated , January 12, 2007, wherein 
you nd provide a revised telephone script for your research study enti tied "An 
examination of regional variation in treating hepatitis C patients in Canada". 
The Co-Chairs of the HIC reviewed your correspondence, approved the revised 
telephone transcript and, granted full approv al of your res arch study. This will 
be reported to the full Human Investigation Committee, for their information at 
the meeting scheduled for February 1, 2007. 
Full approval ha been granted for one year. You will be contacted to complete 
the annual form update approximately 8 weeks before the approval will lapse on 
January 17, 2008. It is your responsibility to ensure that the ren wal form i 
forwarded to the HIC office not less than 30 days prior to the renewal date for 
review and approval to continue the s tudy. The annual renewal form can be 
downloaded from the HIC website 
http: //www.med.mun.ca / hic / downloads/Annual%)20Update<X)20Form.doc. 
Modifications of the protocol/consent are not permitted without prior approval 
from the Human Investigation Committee. Implementing changes in the 
protocol/consent without HIC approval may result in the approval of your 
research study being revoked, necessitating cessation of all related research 
activity. Request for modification to the protocol/consent must be outlined on 
an amendment form (available on the HIC website) and submitted to the HIC 
for review. 
For a hospital-ba d study, it is your responsibility to seek the necessary 
approval from the Health Care Corporation of St. John's and/or other hospital 
boards as appropriate. 
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,--------------------------------
This Research Ethics Board (the HIC) has reviewed and approved the application 
and consent form for the study which is to be conducted by you as the qualified 
investigator named above at the specified study site. This approval and the 
views of this Research Ethics Board have been documented in writing. In 
addition, please be advised that the Human Investigation Committee currently 
operates according to the Tri-Council Policy Statement and applicable laws and 
regulations. The membership of this research ethics board complies with the 
membership requirements for research ethics boards defined in Division 5 of the 
Food and Drug Regulations. 
Notwithstanding the approval of the H IC, the primary responsibility for the 
thical conduct of the investigation remains with you. 
We wish you every success with your study. 
Sincerely, 
John D. Harnett, MD, FRCPC 
Co-Chair 
RichardS. Neuman, PhD 
Co-Chair 
Human Investigation Committee Human Investigation Committee 
JDH;RSN\jed 
C Or. C. Loomis, Vice-President (Research), MUN 
Mr. W. Miller, Director of Planning & Research, Eastern Health 
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